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ABSTRACT 
This thesis describes a new approach for molecular imaging of neuroinflammation in 
Multiple Sclerosis (MS). My aim was to use the 2nd generation TSPO radioligand 18F-
PBR111 to explore the potential of Positron Emission Tomography (PET) targeting 
the 18-kDa Translocator Protein (TSPO), as an in vivo biomarker of activated 
microglia in MS patients. 
This thesis addresses three research objectives. First, I characterised 18F-PBR111 PET 
signal in healthy controls’ brains and tested how it is affected by the TSPO gene 
polymorphism at rs6971. Second, I measured 18F-PBR111 uptake across white matter 
volumes segmented using structural MRI measures related to MS neuropathology. 
Third, I explored how 18F-PBR111 uptake in the hippocampus correlated with 
depressive symptoms and to the brain functional connectivity of the hippocampus.  
Eleven patients with relapsing-remitting MS and 22 age-matched healthy controls 
underwent 18F-PBR111 PET and MRI scans. Structural and functional MRI sequences 
were used to define conventional MS neuropathological markers and for the 
assessment of functional connectivity, respectively.  
I discovered that white matter 18F-PBR111 PET signal in healthy volunteers varied 
with TSPO genotype and correlated positively with age. In patients with MS, signal 
intensity in MRI-defined lesions was higher than that in normal-appearing white 
matter and correlated with the historical rate of progression of their disability. 
Hippocampal 18F-PBR111 uptake was higher in the MS patient group than in healthy 
volunteers and correlated with both depressive symptoms and functional connectivity 
of the hippocampus with frontal, temporal and parietal cortex.  
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I thus discovered that this 2nd generation TSPO PET radiotracer, used in humans for 
the first time in our study, is sensitive to MS neuropathology consistent with 
recognized patterns of microglial activation and that differences between subjects can 
be related to disability progression.  I also have discovered a novel relationship 
between this measure of hippocampal microglial activation and affective symptoms of 
MS. 
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Chapter 1. Background 
1.1 Multiple Sclerosis  
1.1.1 Brief history 
Individual case reports of Multiple Sclerosis (MS) were described already in the 19th 
century. The first clinical description that is now recognized with confidence as a case 
of MS is that of Augustus d’Este (1794-1848), an illegitimate grandson of King 
George III of England, who kept a diary for 26 years in which he recorded the 
progressive course of symptoms, with transient visual impairment, and subsequent 
episodes of motor symptoms and weakness of the lower extremities compromising his 
ability to walk (Landtblom et al., 2010). For decades, similar conditions characterised 
by episodic and progressive neurological deterioration, were labelled as ‘paraplegia’.  
Jean-Martin Charcot provided a definitive description of MS in the mid 19th century, 
by detailing macroscopic and microscopic illustrations of his histopathological 
observations that included lesions, axonal transections and remyelination, and named 
the disease ‘Sclerose en plaques’. It was through a series of Charcot’s public lectures 
in 1868, in which he illustrated the key features of MS, that the concept of MS as a 
discrete disease became rapidly established (Murray, 2009). By the beginning of the 
20th century MS had become one of the most common reasons for admission to a 
neurological ward.  
1.1.2 Epidemiological and clinical considerations 
MS is a chronic, debilitating disease and represents the major, non-traumatic, cause of 
neurological disability.  
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By 2010 the prevalence of MS was approximately 3 per 1000 in women and 1 per 
1000 in men, while the incidence was approximately 10 per 100.000/year in women 
and 5 per 100.000 in men. It is estimated that MS affects approximately 2.5 million 
individuals, of which 125.000 are in the UK (Mackenzie et al., 2014). The annual 
costs per person with MS range between $6.000 and $80.000 (Sharac et al., 2010), 
thus accounting for an estimated 1.2 billion expenditure per annum in the UK. 
For approximately 85% of MS patients the disease starts with a course of recurrent 
and reversible neurological deficits. Relapses usually last no more than a few months 
and the patient regains neurological function. Relapses are defined by the occurrence 
of a new neurological symptom or worsening of an old one, lasting at least 24 hours, 
without fever, and which follows a period of clinical stability or of improvement of at 
least 30 days. The signs and symptoms are variable, including sensory, motor, visual, 
cognitive, and emotional alterations. This phase of the disease is termed relapsing-
remitting MS. After a period that usually ranges between 8 and 20 years, the majority 
of relapsing-remitting MS patients enters a second phase of the disease, named 
secondary progressive MS, characterised by continuous, irreversible neurological 
decline without intermittent relapses. In about a quarter of patients MS never affects 
daily routine activities while up to 15% of patients become severely disabled within a 
short time. A proportion of individuals, accounting for 10–20 % of patients with MS, 
exhibit a progressive disease from onset without episodes of relapse and remission. 
This is classified as primary progressive MS.  
Current diagnostic criteria incorporate evidence from Magnetic Resonance Imaging 
(MRI) and specify that individuals must have a minimum of two attacks affecting 
more than one anatomical site, but, assuming that the initial presentation is suggestive 
of MS, the second lesion needs not necessarily to be clinically expressed (McDonald 
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et al., 2001). Individuals are classified in the categories of MS, not MS, or possible 
MS.  
The onset of the disease is most common in the third or fourth decade, but in 2% of 
patients MS presents before 10 years of age, and in 5% before 16 years of age. 
Overall, the life expectancy is at least 25 years from disease onset, and death usually 
results from unrelated causes. When sensory or visual symptoms dominate the course 
of disease, particularly in young women, the prognosis is relatively good, and there is 
complete recovery from individual episodes. However, in cases where the disturbance 
of coordination and balance are the most prominent features, or in cases of men with 
late onset of disease, the prognosis is less positive. The occurrence of frequent and 
prolonged relapses with incomplete recovery at onset, and a short interval between the 
initial episode and the first relapse, represent adverse prognostic features (Compston 
and Coles, 2002). 
MS has a profound negative impact on the quality of life of patients, caregivers, and 
families, and can restrict professional and personal activities even in early stages. 
Relapses may result in hospitalization and be associated with a level of disability that 
disrupts work, social, and family life. Fixed disability in MS is acquired through two 
distinct mechanisms: incomplete recovery from relapse and disease progression, 
however the main determinant of disability is the onset of the progressive phase. 
Current treatments do not effectively combat the inexorable physical, cognitive, and 
quality-of-life deterioration that many secondary progressive MS patients inevitably 
face.  Disability in MS is commonly quantified in half-point increments using a 
clinician-measured scale, the Kurtzke Expanded Disability Status Scale (EDSS) 
(Kurtzke, 1983). The EDSS quantifies disability in a number of functional systems 
and allows raters to assign a score for each functional system using a 0–10 scale. The 
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functional systems are: pyramidal, cerebellar, brainstem, sensory, bowel and bladder, 
visual, and cerebral. EDSS scores of ≤ 6.5 refer to people with MS who are 
ambulatory whereas EDSS scores of > 6.5 are defined by the impairment to 
ambulation. Therefore, this scale measures disease progression predominantly by 
focusing on deficits in ambulation. 
1.1.3 Non-motor symptoms of Multiple Sclerosis 
Because of the widespread neuropathological involvement, the range of symptoms 
observed in MS patients is broad, and leads to impairments also in systems other than 
those regulating sensory and motor functions.  The disease also causes cognitive 
deterioration and neuropsychiatric symptoms. Classes of symptoms are expressed 
independently, and for example, the manifestation of cognitive and neuropsychiatric 
symptom is not necessary related to motor disability (Zarei, 2006).  
The prevalence of cognitive impairments in MS is high, with rates ranging from 43% 
to 70% (Rao et al., 1991). Deficits can occur at any time throughout the disease 
course. The most prominent cognitive symptoms include deficits in complex 
attention, efficiency of information processing, executive functioning, and long-term 
memory. Processing speed, and visual learning and memory are most commonly 
affected in MS. Verbal skills such as word naming and comprehension are not 
typically affected. General intelligence seems to remain intact in most patients 
(Chiaravalloti and DeLuca, 2008; Rao, 1995). 
Affective symptoms are the most prevalent neuropsychiatric manifestation of MS. 
Depression is the most common psychiatric syndrome, and is a cause of serious 
morbidity and increased mortality in patients with MS (D'Alisa et al., 2006; Feinstein, 
1997). Several studies have concluded that the prevalence of depression in MS 
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exceeds that associated with having one or more other long-term disabling conditions. 
For example, a survey of 115,071 adults living in Canada confirmed an elevated 
prevalence of Major Depression in patients with MS (annual prevalence, 16%), 
relative to both healthy individuals and those with other long-term medical illnesses 
(annual prevalence, 4% and 9% respectively). Patients with MS aged 18–45 years had 
a one in four chance of developing depression over the course of 1 year, while for 
individuals without MS, the rate of depression was one in eleven. The relative risk 
ratio for Major Depression among patients with MS, after adjustment for age and sex, 
was 2.3 (Patten et al., 2003). In another community sample of 1,374 patients with MS, 
depression was present in 41.8% of cases (Chwastiak et al., 2002).  Studies in 
hospital-based samples found a prevalence of depression two-to-five times higher 
than that found in the general population (Feinstein et al., 2014). A possibly unusual 
feature is that, despite the greater prevalence of depression amongst females, an 
association between depression and female gender has not been observed amongst 
people with MS. 
Depression appears to be less common in patients with clinically isolated syndrome, 
the first neurological episode potentially indicative of MS, but there is not a clear 
relationship between disease progression, neurological disability and depression: 
higher rates of depression have been reported in relapsing–remitting MS relative to 
progressive MS (Feinstein et al., 2014) and depression severity is higher in MS 
patients without physical disability relative to controls (Haase et al., 2003).  
Structural brain changes on MRI account for approximately 40% of the variance in 
reports of MS-related depression (Feinstein et al., 2004).  Genetic, biochemical, and 
immunological markers of disease activity also have been associated with depression 
in MS (Feinstein et al., 2014). Together, these data suggest that depression is a direct 
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consequence of the brain pathology underlying MS.  
1.1.4 Neuropathology of Multiple Sclerosis 
MS is characterised by the presence of inflammation, demyelination and 
neurodegeneration at multiple sites throughout the central nervous system (CNS).  
The term ‘neuroinflammation’ is widely used in my thesis, although is not easy to 
define. While it is often used to specifically indicate a CNS-specific glial response of 
the innate immunity, namely the activation of microglia and astroglia such as that 
observed in chronic neurodegenerative diseases, it is worth recognizing that the 
inflammatory pathology in MS is not only restricted to glial activation, but also 
encompasses various acute “classic” inflammatory phenomena such as the presence 
of perivascular infiltrates of cells, and a prominent involvement of the adaptive 
immune system. Accordingly, the term ‘neuroinflammation’ is used in this thesis to 
indicate diverse inflammatory responses taking place in the brain, including both 
those of glial as well as peripheral origin.  
In MS, focal areas of inflammatory demyelination in which lymphocytes infiltrate 
perivascular spaces, and myelin, oligodendrocytes and axons are destroyed, cause the 
reversible disability in relapsing-remitting MS. The blood-brain barrier (BBB) is 
compromised and lesion areas become edematous. Astrogliosis eventually occurs in 
the demyelinating plaques and results in a gliotic scar.  
Ex vivo pathology studies show that the acute, active lesions are characterised by a 
hypercellular inflammatory core, marked by prominent lymphocyte infiltration with a 
high density of activated microglia or macrophages distributed evenly throughout the 
lesion (Trapp et al., 1999). In chronic active lesions, microglia are increased relative 
to distant normal white matter tissue and are more concentrated at the lesion edge 
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than within the lesion. A hypercellular margin, characterised by a high density of 
activated microglia surrounding demyelinating plaques, is a consistent finding across 
neuropathological studies (Boyle and McGeer, 1990; Lucchinetti et al., 2000; Marik 
et al., 2007).    
Historically, MS has been considered primarily as a white matter disorder, however 
renewed examination of cortical grey matter revealed that the prevalence of cortical 
lesions is high and that demyelination takes place also in the cerebral cortex and deep 
grey matter of MS patients, and is associated with neuronal loss with scarce 
inflammatory infiltration (Geurts and Barkhof, 2008; Kidd et al., 1999; Magliozzi et 
al., 2010). On the other hand, lymphocytic infiltrates in the leptomeninges have been 
commonly observed in postmortem MS brain (Magliozzi et al., 2007). 
Diffuse changes, away from macroscopic lesions, are visible in the normal appearing 
white and grey matter. These observations included: the presence of microglia 
activation and axonal pathology associated with changes at the Node of Ranvier, i.e. 
the disruption of paranodal axoglial junctions (Howell et al., 2010); and the so-called 
“pre-active lesions” (De Groot et al., 2001), focal areas of activated microglia without 
apparent loss of myelin that may be at risk for the development of acute inflammatory 
lesions (Henderson et al., 2009; Marik et al., 2007). 
Acute perivascular inflammatory infiltrates associated with changes in BBB 
permeability are responsible for acute relapses, while the resolution of inflammation 
and remyelination is thought to contribute to the clinical recovery and remission 
during the relapsing-remitting phase (Kutzelnigg and Lassmann, 2014).  
The secondary progressive phase appears to be characterised by a relatively intact 
BBB, and inflammation becomes increasingly compartmentalized in the perivascular 
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and subarachnoid spaces. The clinical progression is thought to be a consequence of 
an accumulating burden of transected axons and damaged neurons associated with 
more advanced progression of brain atrophy (Trapp and Nave, 2008). However, 
diffuse tissue damage in the non-lesional brain tissue, unrelated to axonal damage, 
also contributes to disease progression. There is evidence that grey matter 
pathological changes importantly contribute to clinical disease severity (Reynolds et 
al., 2011). These changes are already present in early stages of the disease, and 
become more prominent when the disease progresses (Chen et al., 2004a; De Stefano 
et al., 2003).  
1.1.5 Role of microglia 
In MS, the areas of tissue damage and demyelination are rich in activated microglia 
(Bauer et al., 1994). Microglia have a mesodermal origin and represent the resident 
immunocompetent cells in the CNS. They have been described as sensors for 
pathological events in the CNS (Kreutzberg, 1996). Microglia in the healthy, mature, 
CNS have a ramified morphology consisting of a small soma with fine cellular 
processes. This has been classically associated with microglial “resting” state. 
Pathological signals such as infection, trauma, ischemia, neurodegenerative diseases, 
or altered neuronal activity, as well as any other disturbance of brain homeostasis 
indicating real or potential danger to the CNS, all can evoke rapid and profound 
changes in the microglial cell shape, gene expression and the functional behavior 
which summarily is defined as “microglial activation”.  
Microglia activation is characterised by a set of stereotypical changes, such as change 
in morphology, migration of microglia towards the site of damage following 
chemotactic gradients, proliferation, rearrangement of cell surface molecules for cell-
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cell and cell-matrix interactions, and release of pro-inflammatory molecules. Release 
of chemoattractive factors recruits and guides immune cell populations to the CNS, 
and presentation of antigens to T-lymphocytes can subsequently trigger an adaptive 
immune response.  Further, microglia’s phagocytic activities clear tissue debris, 
damaged cells, or antibody–coated and opsonised antigens.  In addition to their 
phagocytic role, microglia synthesize and secrete potential neurotoxins that may cause 
neuronal damage. Also, the range of microglial activities also covers production of 
neurotrophic factors and the physical association with endangered neurons 
(Kettenmann et al., 2011; Kreutzberg, 1996; Venneti et al., 2006).  
Microglia contribute to MS pathology through several mechanisms including the 
presentation of antigens and secretion of proinﬂammatory cytokines, initiating an 
acute inflammatory response; the clearance of damaged tissue, a property potentially 
linked both to recovery of function and to recurrence of relapses; and the production 
of toxic mediators leading to irreversible tissue injury associated with the progressive 
disease phase (Jack et al., 2005). Microglia may also exert a protective function in MS 
as they can promote tissue regeneration and repair (Muzio et al., 2007). 
Activated microglia may represent an early stage of tissue injury, which precedes the 
formation of demyelinated plaques, but at the same time it can contribute to 
progressive neurodegeneration. For these reasons, microglial activation has the 
potential to become a useful tool to monitor early neuroinflammatory processes, 
disease progression and response to treatment in MS. 
Histopathological data have also evidenced the presence of microglial activation in 
cortical lesions, which included significant microglial distribution and association of 
microglia with neuronal elements (Peterson et al., 2001).  
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1.2 Neuroimaging hallmarks of inflammation in Multiple Sclerosis 
The most frequently used imaging tool to identify in vivo biomarkers in MS is MRI. 
MRI has an established role in the diagnosis of MS, and has been used to investigate 
the natural course of the disease and monitor treatment effects in clinical trials. In 
relapsing-remitting MS patients, the effect of a treatment on MRI-based measures and 
its effect on the frequency of relapses and short term progression of disability are 
strongly correlated, supporting the use of MRI parameters as surrogates for clinical 
end points (Sormani et al., 2014; Sormani et al., 2009).  
However, changes in MRI measures of inflammatory activity correlate weakly with 
disability progression in secondary-progressive MS (Goodin, 2006). At high levels of 
disability, a plateauing relationship is commonly observed between T2-weighted 
hyperintensities and disability, indicating that other factors should be considered 
when assessing the more advanced phase of the disease (Li et al., 2006). 
Although data derived from post-mortem pathology suggest widespread cortical 
involvement in MS, it is currently difficult to accurately assess the contribution of 
cortical pathology with routinely available MRI imaging techniques. T1-weighted and 
T2-weighted MRI detects only a minority of cortical lesions. This may be due to the 
different pathophysiology of cortical grey matter lesions, compared to those in the 
white matter, with less inflammatory cell infiltration and absent BBB damage 
(Peterson et al., 2001). A detailed study comparing the number of cortical lesions 
detected by histopathology and post-mortem MRI, applying dual-echo T2-weighted 
spin-echo images and Fluid Attenuated Inversion Recovery (FLAIR), yielded 
detection rates of FLAIR images of only 5% for intracortical, 41% for leukocortical, 
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and 38% for deep grey matter lesions (Geurts et al., 2005a). The detection of 
periventricular and juxtacortical lesions has been greatly improved with double 
inversion recovery and phase sensitive inversion recovery (Calabrese et al., 2010; 
Geurts et al., 2005b; Nelson et al., 2007), however intracortical and subpial lesions 
remain difficult to detect with current MR imaging resolution. The use of high-field 7 
Tesla MRI also holds promises to improve the detection of cortical lesions (Tallantyre 
et al., 2008; Tallantyre et al., 2010). 
Despite the importance of MRI in transforming the clinical diagnosis of MS and the 
development strategies for new drugs, MRI measures are also limited by their lack of 
neuropathological specificity. For example, hyperintensities on T2-weighted images 
non-specifically reflects edema, demyelination or astrogliosis (Arnold and Matthews, 
2002).  
Microglia constitute an attractive cellular target with an improved pathological 
specificity for imaging of neuroinflammation. Also, the possibility of visualization of 
activated microglia would have the potential of enabling the characterisation of 
neuroinflammatory involvement in normal appearing white matter and in cortical grey 
matter as well, which can ultimately contribute to predict disease progression and 
study the relationship between cortical pathology and related clinical symptoms, such 
as emotional and cognitive alterations.  
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1.3 Targets for molecular imaging in Multiple Sclerosis 
Molecular imaging, based on the in vivo administration of radiolabelled ligands that 
bind selectively to a target of interest, offers the potential of high specificity for 
molecular markers of cellular and metabolic processes. The high selectivity of 
Positron Emission Tomography (PET) allows microdosing of the radiotracer, 
ensuring high safety and tolerability for the subjects who undergo the procedure. 
Currently, there is a great potential for the application of molecular imaging in MS in 
the assessment of inflammatory responses, myelin imaging and quantitative 
measurement of neuronal function. Molecular imaging could be also used to test 
novel therapeutics, in order to ascertain whether they reach the target and have the 
desired pharmacodynamic action (Matthews et al., 2011). 
Although for more than a decade there has been a great interest and intense research 
in the identification of suitable PET targets for imaging the brain in MS, only a 
limited number of targets have been investigated in living patients to date. The most 
extensively characterised PET target is the 18-kDa Translocator Protein (TSPO). 
Preliminary evidence also indicates the potential use of the adenosine 2A receptors 
(A2ARs) and some myelin components as additional PET targets for imaging in MS. 
Other targets hold promise for future application, for example receptors such as the 
gamma-aminobutyric acid-A (GABAA) receptor, cannabinoid-2 (CB2) receptor, 
acetylcholine and some purinergic receptors, and cellular components such as 
phosphatidylserine. So far, however, these have been only tested in vitro, in 
preclinical experimental models of autoimmune encephalomyelitis, or in 
neuroinflammatory and neurodegenerative conditions other than MS.  
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1.4 The Translocator Protein 
1.4.1 Physiology and expression in the brain 
The TSPO was formerly known as the peripheral benzodiazepine receptor (PBR). It 
was identified as a benzodiazepine receptor that was pharmacologically, anatomically, 
structurally, and physiologically distinct from the classic benzodiazepine receptor 
found in the CNS. The TSPO is a protein localized on the outer mitochondrial 
membrane, and although is primarily located in the mitochondria, it has been also 
found in red blood cells (which are devoid of mitochondria) or in the cell membrane 
and in the nucleus and perinuclear area in different cell lines (Chen and Guilarte, 
2008). 
The TSPO has several biological functions, the most characterised being the control 
of cholesterol transport associated with steroid synthesis. The TSPO is abundantly 
expressed in steroidogenetic tissues where it mediates transport of cholesterol from 
cytosol into mitochondria (Papadopoulos et al., 2006), where the synthesis of steroids 
from cholesterol takes place. The other physiological functions attributed to the TSPO 
are heme biosynthesis, control of autophagy and apoptosis, synthesis of bile acids, 
calcium flow, production of reactive oxygen species, chemotaxis and cellular 
immunity, and mitochondrial respiration [for review see (Chen and Guilarte, 2008)].  
The TSPO appears to be involved in basic housekeeping functions and was 
hypothesized to be essential for embryonic development, although a recent report 
suggested that TSPO global knock-out mice are viable and are capable of 
steroidogenesis (Tu et al., 2014). 
A number of endogenous ligands that bind to the TSPO have been proposed. One 
putative endogenous ligand is the diazepam binding inhibitor or endozepine (Guidotti 
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et al., 1983). Cholesterol is also considered an endogenous ligand for the TSPO with 
nanomolar affinity (Lacapere et al., 2001). Other potential endogenous ligands are the 
porphyrins (protoporphyrin IX, mesoporphyrin IX, deuteroporphyrin IX, hemin), 
which exhibit a very high affinity for the TSPO (Snyder et al., 1987).  
In normal conditions the TSPO is highly expressed in peripheral tissues, particularly 
where steroids are synthesized. In the normal human brain, the expression of the 
TSPO is low. A study mapped the cellular localization and the degree of expression of 
the TSPO by immunohistochemistry in post-mortem brain tissue of subjects without 
neurological conditions. The TSPO was mainly expressed in macrophages and 
microglia, astrocytes, oligodendrocytes, endothelial cells and smooth muscle cells. 
TSPO was present in subpial and subependymal glia, meninges (vessels, macrophages 
and sometimes arachnoid cells), ependymal cells, and choroid plexus. Some punctate 
staining was found in neuronal cell bodies too (Cosenza-Nashat et al., 2009).  
Autoradiography studies using radiolabelled TSPO ligands demonstrated that the 
expression of the TSPO is enhanced on activated microglia and, in the case of a 
disrupted BBB, on invading cells of mononuclear-phagocyte lineage, including 
macrophages and monocytes (Chen and Guilarte, 2008; Venneti et al., 2006). Some 
studies have suggested the presence of increased TSPO expression on astrocytes, 
however the relative contributions of astrocytes versus microglia to the binding of 
TSPO radioligands in neuroinflammation has been a subject of continuing debate 
(Venneti et al., 2006). 
The lack of cellular specificity of TSPO binding implicates that various cell types are 
likely to contribute significantly to the signal obtained by PET with TSPO-specific 
radioligands. The global detectable signal is most likely resulting from the 
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combination of TSPO radioligand binding to microglia, macrophages, monocytes, 
astrocytes and endothelial cells. A recent study (Rizzo et al., 2014) suggested that the 
presence of TSPO binding sites on the endothelial layer of blood vessels is of 
particular interest for imaging purposes, as it might potentially affect the accuracy of 
quantification of PET data using a second-generation high affinity TSPO PET 
radioligand. 
The mechanisms responsible for increased TSPO expression in microglia in the CNS 
are not known. In the periphery, such as pancreatic islet cells, Leydig cells, and 
cultured astrocytes, proinflammatory cytokines cause an increase in TSPO mRNA 
and TSPO ligand binding. It has been proposed that the cellular upregulation of TSPO 
may serve as a protective strategy against cytokine toxicity. Since activated microglia 
themselves are sources of cytokines, the increase in TSPO expression has been 
proposed to represent an autocrine-paracrine phenomenon (Venneti et al., 2006). A 
recent study demonstrated that specific TSPO ligands increased the proliferation and 
phagocytosis of resting microglial cells and led to increased production of reactive 
oxygen species, while, conversely TSPO ligands reduced the expression of 
proinflammatory genes and cytokine release of activated microglia (Choi et al., 2011). 
1.4.2 Autoradiography studies in Multiple Sclerosis 
To ascertain whether increases in TSPO radiotracers binding are specific to activated 
microglia in the brain of MS patients, a number of autoradiography studies have been 
conducted in post-mortem brain tissues obtained from MS patients. Focal increases in 
binding of the TSPO radioligands 3H-PK11195, 3H-DAA1106 and 3H-PBR28 have 
been found in the brain of MS patients (Banati et al., 2000; Benavides et al., 1988; 
Owen et al., 2010; Venneti et al., 2008). Banati and coworkers demonstrated the 
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highest 3H-PK11195 binding in MS plaques, but areas of increased binding were also 
found on activated microglia outside the histologically-defined borders of MS 
plaques, as well as in areas of normal appearing grey matter. These experiments have 
been also able to elucidate the relative contribution of reactive astrocytes and 
activated microglia to the binding of TSPO ligands, as most of the studies showed that 
the increased binding of 3H-PK11195 and 3H-DAA1106 was mostly co-localized with 
immunohistochemistry markers of activated microglia, rather than astrocytes (Banati 
et al., 2000; Owen et al., 2010; Venneti et al., 2008; Vowinckel et al., 1997). Further, 
these studies demonstrated that 3H-DAA1106 and 3H-PBR28 bind to TSPO with 
higher affinity for TSPO, relative to 3H-PK11195.  
Based on the evidence from autoradiography studies that TSPO radiotracer binding 
reflects presence of activated microglia, PET with TSPO radiotracers has been used to 
visualize neuroinflammatory processes in vivo. Figure 1.1 illustrates the use of TSPO 
PET imaging to visualize microglia, reflecting neuroinflammatory pathology, in MS 
patients. 
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Post-mortem 
studies 
Radioligand Findings 
 Benavides et al., 
1987 
3H-PK11195  Areas of high specific binding colocalized with 
demyelinating plaques within the white matter 
Vowinckel et al., 
1997  
3H-PK11195  Binding correlated with CD68-labeled activated 
microglia  
Banati et al., 2000  3H-PK11195  Areas of high specific binding colocalized with 
demyelinating plaques within the white matter and 
with oil red O-positive macrophages and EBM11-
positive microglia  
Venneti et al., 
2008  
3H-PK11195   
3H-DAA1106 
Binding correlated with CD68-labeled activated 
microglia  
Owen et al., 2010  3H-PK11195  
3H-PBR28 
Areas of high specific binding colocalized with 
demyelinating plaques within the white matter 	  
Table 1.1 TSPO autoradiography studies 
 Correlation between TSPO radioligand binding and correlation with 
immunohistochemistry markers of activated microglia and demyelination in post-
mortem MS brain. 
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Figure 1.1 Schematic representation of the rational underlying the use of 
TSPO PET imaging to visualize neuroinflammation in MS 
The activation of microglia due to neuroinflammatory processes is associated with the 
upregulation of TSPO, leading to the increase of available TSPO for PET radioligand 
binding. The brain images on the right have been obtained with PET and 11C-(R)-
PK11195 in a healthy volunteer (top) and a patient with MS (bottom) (Politis et al., 
2012).   
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1.4.3 First generation TSPO PET studies in Multiple Sclerosis 
The most studied TSPO radiotracer is 11C-(R)-PK11195, which has been used for 
more than a decade. Newer radiotracers have been recently tested, and preliminary 
data on their application as tools for imaging in MS is now available.  
Studies have showed an increased uptake of 11C-(R)-PK11195 in various neurological 
disorders other than MS, namely Human Immunodeficiency Virus encephalitis, 
Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, multiple system 
atrophy, stroke, amyotrophic lateral sclerosis, CNS neoplasms, and traumatic brain 
injuries (reviewed in Cagnin et al., 2007 and Venneti et al., 2006).  
Nine 11C-(R)-PK11195 PET studies in MS patients have been reported. The studies 
are summarized in Table 1.2. In general, an increased 11C-(R)-PK11195 uptake was 
found in MS brain compared to matched healthy controls. While in healthy 
volunteers, the brain uptake of 11C-(R)-PK11195 was found to be extremely low, in 
MS patients areas with increased uptake were consistently observed to correspond to 
white matter Gadolinium-enhancing lesions (Banati et al., 2000; Debruyne et al., 
2002; Debruyne et al., 2003; Vowinckel et al., 1997). An increased 11C-(R)-PK11195 
binding has been observed in the majority of hypointense T1-weighted MRI lesions 
(Giannetti et al., 2014). Moreover, studies indicated that there were focal areas of 
increased 11C-(R)-PK11195 uptake also in normal appearing grey and white matter 
areas, thalamus, and periventricular white matter indicating that TSPO PET was able 
to visualize also diffuse inflammatory processes in areas which appeared normal on 
MRI (Banati et al., 2000; Rissanen et al., 2014). The overlap between MRI lesions 
and increased radioligand uptake was higher during relapses (Banati et al., 2000), 
consistent with the role of activated microglia in active acute MS lesions (Peterson et 
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al., 2001).   A positive correlation has been suggested between ligand uptake and 
disease duration, disability, and brain atrophy (Banati et al., 2000; Debruyne et al., 
2003; Versijpt et al., 2005), however the correlations were not consistently replicated 
across different studies. Also, the observed differences between MS patients versus 
controls in 11C-(R)-PK11195 normal-appearing grey and white matter parenchymal 
binding have not been consistent across studies. Although the studies by Banati found 
an increased radioligand uptake in the thalamus and brain stem of MS patients 
compared to healthy controls (Banati et al., 2000; Rissanen et al., 2014), in 
Debruyne’s study the authors didn’t find any between-groups differences in the areas 
outside lesions (Debruyne et al., 2003).  Also, the latter study found a decreased 
uptake in T2-lesions compared to normal appearing tissue, while an increased 11C-
(R)-PK11195 uptake was associated with relapses. The authors suggested that the 
upregulation of TSPO may be transient, however issues related to different 
quantification methods may account for the differences found in this study compared 
to others. 
Interestingly a recent study, which was specifically focused on cortical pathology, 
found an increase in cortical grey matter 11C-(R)-PK11195 uptake in MS patients 
relative to healthy controls, which was more pronounced in secondary progressive 
than relapsing-remitting patients (Figure 1.2). There was a significant correlation 
between high cortical 11C-(R)-PK11195 uptake and disability as measured with 
EDSS, and this relationship was stronger for the subgroup of secondary progressive 
MS patients (Politis et al., 2012). The distribution of increased signal was not uniform 
across the cortical grey matter, and the cortical regions with highest increase included 
pre-central and post-central gyri. The uptake in the white matter was also increased in 
MS patients relative to controls, however there was no relationship between disability 
	  	  
43 
and white matter uptake. This in vivo evidence of cortical involvement in MS 
pathology, predictive of MS disability, is consistent with recent neuropathological 
studies that described the presence of subpial grey matter demyelination secondary to 
the presence of substantial meningeal inflammation in some cortical sulci (Magliozzi 
et al., 2010). Importantly, meningeal inflammation was associated with an increased 
density of activated microglia and substantial neuronal loss in grey matter lesions of 
the precentral gyrus of secondary progressive MS patients (Howell et al., 2011; 
Magliozzi et al., 2007; Magliozzi et al., 2010), which is consistent with the findings of 
the PET imaging evidence (Politis et al., 2012).  
Only one longitudinal study has been conducted so far. The authors investigated the 
effects of 1 year-treatment with glatiramer acetate, an immunosuppressive agent 
commonly used as a treatment of relapsing-remitting MS, on the uptake of 11C-(R)-
PK11195 in nine previously untreated relapsing-remitting MS patients. A significant 
decrease was noted in cortical gray matter and cerebral white matter, and a trend 
towards decreased uptake was seen in the putamen and thalamus (Ratchford et al., 
2011). However, these finding should be considered preliminary as the study didn’t 
include a control group and the sample size was small.  
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Figure 1.2       Examples of 11C-(R)-PK11195 PET images 
These images display the TSPO density in the brain of (A) a healthy 40-year-old 
woman, (B) a 46-year-old man with a 12-year history of relapsing-remitting MS and 
(C) a 46-year-old woman with secondary progressive MS and a 26-year disease 
duration (from Politis et al., 2012).  
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The first and best characterised TSPO tracer 11C-(R)-PK11195 is hampered by a poor 
signal-to-noise (SNR) ratio, which complicates its quantification (Banati et al., 2000; 
Shah et al., 1994). This is a result of a combination of factors, the most significant of 
which is that 11C-(R)-PK11195 binds non-specifically to other sites in addition to 
TSPO (Owen et al., 2010). Moreover, 11C-(R)-PK11195 also suffers from low brain 
penetration (Debruyne et al., 2003; Vas et al., 2008). As a consequence of these 
factors, only very low signal from 11C-(R)-PK11195 is found in the normal brain, 
resulting in a poorly defined pattern of binding.  
The quantification of 11C-(R)-PK11195 is further complicated by the ubiquitous 
distribution of TSPO, with a lack of a region that is devoid of TSPO binding. This 
complicates the definition of a normal reference tissue and becomes particularly 
problematic in diseases that are disseminated throughout the brain, such as MS.  
The most common method used for quantification of 11C-(R)-PK11195 brain uptake 
is cluster analysis, which was developed originally by the Hammersmith Hospital 
group in London. To derive a pseudo-reference Time Activity Curve (TAC), 11C-(R)-
PK11195 binding in control subjects has been used to represent a minimum or basal 
level of TSPO binding. It has been assumed that 11C-(R)-PK11195 uptake in control 
subjects would have a similar shape to a reference TAC, representative of normal 
tissue, in patients. By applying cluster analysis to patient studies, several TACs could 
be extracted and their shapes were compared against the control curve. The cluster 
TAC that appears most consistent with the control TAC is used as a reference curve 
for the patient study. A refined method, named Supervised clustering analysis 
(SuperPK) (Turkheimer et al., 2007) has been based on the characterisation of kinetic 
classes of 11C-(R)-PK11195 uptake. Other modelling techniques include the 
normalisation to either the white or grey matter. The former is based on the notion 
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that 11C-(R)-PK11195 uptake in the white matter provides a stable level activity that 
can be used as a reference for evaluating the binding level in other regions. The latter 
consists of sampling different grey matter regions, with the region with lowest 
determined uptake taken as the reference region (Debruyne et al. 2003).  
Blood input compartmental modelling has been also used with a blood input function, 
which is always considered the gold standard method of quantification. However, the 
accurate quantification of a blood input function was found to be complicated due to 
the highly variable kinetic behavior of 11C-(R)-PK11195 in plasma. This unstable 
kinetic behavior has been attributed to variable plasma protein binding, in particular 
high binding to alpha1-acid glycoprotein (Lockhart et al., 2003). This can potentially 
contribute to the access of 11C-(R)-PK11195 to the brain parenchyma in diseases with 
BBB breakdown, such as MS, therefore providing a source of brain uptake of 11C-(R)-
PK11195 which is independent of TSPO.  
Due to the limitations reported above, there has been great interest in the development 
of newer TSPO radioligands with improved imaging characteristics. 
1.4.4 Second generation TSPO PET radioligands 
Only three TSPO PET radiotracers, other than 11C-(R)-PK11195, have been used in 
MS patients to my knowledge. A study compared the uptake of 11C-(R)-PK11195 and 
that of the tracer 11C-vinpocetine in 4 MS patients.  The global uptake of vinpocetine 
was approximately 50% higher compared to 11C-(R)-PK11195. The regional and the 
perilesional uptakes were also investigated. The binding was higher for 11C-
vinpocetine in the frontal lobe, thalamus, and perilesional regions. Interestingly, the 
correlation between the binding values of the two tracers within the same regions was 
weak. Also, the kinetic behaviours of the ligands were also different in the 
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perilesional region, perhaps indicating that the two ligands bind differentially to the 
TSPO (Vas et al., 2008). However, the limitations inherent to small sample size and 
the choice of the reference region may have accounted for the discrepancies observed.  
The recently developed TSPO radioligand 11C-PBR28, with high affinity for TSPO in 
vitro and high brain penetration, was applied to MS patients in a study by Oh and 
coworkers (2010). Eleven MS patients and 7 healthy controls were studied, and a 
follow-up scan in 6 MS patients was also obtained. The results indicated that 
parenchymal 11C-PBR28 binding did not differ between MS patients and healthy 
controls, however an altered distribution of TSPO expression in the MS brain was 
suggested, based on a higher white matter-to-grey matter ratio of 11C-PBR28 uptake 
in MS patients relative to controls. No relationship was observed between 11C-PBR28 
binding and MRI-based lesion load. Focal increased binding was observed to 
correspond to Gadolinium-enhancing lesions, and, importantly, the comparison 
between baseline and follow-up scans indicated that increased focal 11C-PBR28 
binding preceded the development of new Gadolinium-enhancing lesions. 
A recent investigation using the novel tracer 18F-FEDAA1106 in 9 MS patients in 
acute relapse and 5 healthy controls, also did not report any significant differences 
between patients and controls in any examined region of interest, and there was no 
evidence of any higher uptake in MRI-identified MS lesions relative to surrounding 
areas (Takano et al., 2013).  
Other potential novel TSPO radiotracers that are promising for application in MS 
patients include: 18F-PBR111, 11C-DPA713 and 18F-PBR06, which are promising 
ligands tested in autoradiography assays on post-mortem MS brain tissues (Owen et 
al., 2011) and evaluated through 11C-DAC and the SPECT tracer 123I-CLINDE have 
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been successfully tested in the rodent model of MS, the experimental autoimmune 
encephalomyelitis. There are a variety of other TSPO ligands which are currently 
tested in healthy subjects and for other neurological conditions, for a comprehensive 
review see (Chauveau et al., 2008). 
Some of the 2nd generation TSPO radioligands that have been introduced offer higher 
specific to non-specific signal. A study of our group, using a biomathematical model 
based on in silico/in vitro data (Guo et al., 2009; Guo et al., 2012) predicted that the 
2nd generation TSPO radioligands 18F-PBR111, 11C-PBR28, and 11C-DPA713 would 
perform better in vivo than 11C-(R)-PK11195 and that these radioligands would give 
greater power to detect group differences than 11C-(R)-PK11195, and as a result, 
fewer subjects may be required to detect mild-to-moderate TSPO increase in 
neurological populations (Guo et al., 2012).  
1.4.5 Variation in the affinity of novel radioligands for TSPO  
 
The use of 2nd generation TSPO radioligands, in particular 11C-PBR28, became 
complicated by the discovery of the existence of apparent “non-binders”, subjects that 
appear not to bind 11C-PBR28. In vitro radioligand binding studies using post-mortem 
human brain tissue revealed substantial population variation in the affinity of 11C-
PBR28 for the TSPO. “Low Affinity Binders” (LABs) have a marked reduction in 
affinity for 11C-PBR28 (Ki ~ 188 nM) in comparison to “High Affinity Binders” 
(HABs, Ki ~ 3.4 nM). Hence LABs do not produce a measurable specific signal in 
PET studies with 11C-PBR28 and appear as “non-binders”(Owen et al., 2010).  A 
third group was also identified [“Mixed Affinity Binders” (MABs)], who express the 
HAB and LAB binding sites in approximately equal number (Owen et al., 2010). This 
variation in binding affinity is not specific to 11C-PBR28; all the tested 2nd generation 
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TSPO radioligands behave in a similar manner (Owen et al., 2011). In contrast, 11C-
(R)-PK11195 binding in the brain doesn’t vary between HABs, MABs, and LABs. 
The reason for this is not clear, but one hypothesis is that different binding sites 
within TSPO molecule, for different radiotracers, account for this difference between 
11C-(R)-PK11195 and 2nd generation tracers. 
Interestingly, the variation in binding affinity of 2nd generation tracers was found to 
be due to a single nucleotide polymorphism (SNP), rs6971, in the gene encoding the 
TSPO (Owen et al., 2012), which causes a substitution of threonine and alanine at 
position 147 (Ala147Thr). This substitution is common in Caucasians: 49% of 
subjects are Ala-Ala (HABs), 42% are Ala-Thr (MABs), and 9% are Thr-Thr (LABs), 
but its prevalence varies across ethnic groups. Since the binding class is consistent 
within each subject for all the 2nd generation ligands tested to date, genotyping the 
rs6971 polymorphism can help the quantitative assessment of TSPO ligand binding, 
by allowing binding affinity to be predicted at screening. The functional role of the 
rs6971 SNP is unclear, however in a case-control study based on two large datasets, 
we previously found an association between this polymorphism and manifestation of 
Bipolar Disorder suggesting that rs6971 is a functional SNP (Colasanti et al., 2013). 
Despite the possibility of predicting the classes of binding affinity at screening is very 
important for the application of 2nd generation ligands in basic and pharmacological 
research, the presence of a variation in binding affinity across the population may still 
be impractical for the clinical application of these tracers. For example, genotyping 
would be necessary in all the patients undergoing PET imaging with 11C-PBR28, in 
order to distinguish those who are HABs from those who are MABs, and in 
approximately 10% of the population (LABs) the specific signal of 11C-PBR28 would 
not be measurable in any case.  
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Table 1.2 PET studies using TSPO radioligands in MS patients 
Author Subjects PET ligand Results 
Vowinckel et al. (1997)  2 MS  11C-PK11195 High focal 11C-PK11195 binding in MRI-
Gadolinium active lesion 
Banati et al. (2000) 12 MS;      
8 HV 
11C-PK11195 Higher global and Gadolinium-active 
lesions binding in MS relative to HVs 
Debruyne et al. (2003)  22 MS;      
7 HV 
11C-PK11195 
 
No group difference in global 11C-
PK11195 binding; higher binding in 
Gadolinium-active lesions relative to 
normal appearing brain. Higher binding in 
T2 lesions of MS patients during relapses 
compared to HVs. Positive correlation 
between 11C-PK11195 binding and 
disease duration 
Versijpt et al. (2005)  24 MS;      
8 HV  
11C-PK11195 
 
Positive correlation between 11C-
PK11195 binding in normal appearing 
white matter and brain atrophy. Negative 
correlation between binding in T2 lesions 
and atrophy 
Vas et al. (2008) 4 MS 11C-PK11195 
11C-vinpocetine 
Higher global uptake for 11C-vinpocetine 
relative to that of 11C-PK11195. 
Differences between ligands in binding in 
peri-plaque region 
Oh et al. (2010) 11 MS;       
7 HV 
11C-PBR28 
 
No group difference in global 11C-PBR28 
binding; higher binding in Gadolinium-
active lesions relative to normal appearing 
brain. Increased 11C-PBR28 binding 
preceded appearance of Gadolinium-
enhancement 
Ratchford et al. (2012)  9 MS  11C-PK11195 
 
Decrease in global and regional 11C-
PK11195 binding after 1 year of 
glatiramer acetate treatment 
Politis et al. (2012) 
 
 
 
 
 
Takano et al. (2013) 
16 MS;      
8 HV 
 
 
 
 
9 MS; 
5 HV 
 
11C-PK11195 
 
 
 
 
 
18F-FEEDA1106 
Higher cortical grey matter 11C-PK11195 
binding in secondary-progressive MS. In 
secondary-progressive MS, positive 
correlation between cortical grey matter 
binding and MS disability 
 
No differences between MS patients and 
healthy controls 
Giannetti et al. (2014)      19 MS 11C-PK11195 
 
Higher 11C-PK11195 binding in 76% of 
black-holes. In secondary-progressive 
MS, positive correlation between black-
holes binding and disability 
Rissanen et al. (2014) 10 MS, 
8HV 
11C-PK11195 
 
Higher 11C-PK11195 binding in peri-
ventricular & normal-appearing WM and 
thalamus  in secondary progressive MS 
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1.5 Rationale and Aims of the thesis 
1.5.1 Rationale for the choice of 18F-PBR111 
More than 50 candidate 2nd generation TSPO PET radioligands have been introduced 
in the last five years (reviewed in Chauveau et al., 2008). However, when the current 
project was designed, data on in vivo application were available only for a limited 
number of radioligands. Of these, a number had been tested in humans (18F-FEDAA 
1106; 11C-PBR28; 11C-AC5216; 18F-PBR06; 11C-DPA713; 11C-Vinpocetine), while 
for others only data on application in rodents and non-human primates was available 
(18F-PBR111, 18F-FEPPA, 18F-DPA714; 11C-DAA1106). 
The analysis of existing evidence from human and preclinical applications, as well as 
in vitro observations of our group, led us to select 18F-PBR111 for initial evaluation in 
studies of MS patients and healthy controls. Fluorine 18-radiolabelled tracers offer the 
advantage over similar carbon-11 molecules of a longer radioisotope half-life that 
could allow the use of the radiotracer also in PET centers where de novo 
radiosynthesis is not possible. 
Initial characterisation in biodistribution studies in rodents suggested 18F-PBR111, 
amongst various fluorine-18 candidates in the public domain, had optimal 
characteristics in terms of selectivity and specificity of its signal for TSPO. In a study 
using an acute lesional model of neuroinflammation in rats, 18F-PBR111 was found to 
be metabolically stable and display high in vivo binding to TSPO (Fookes et al., 
2008). Furthermore, a pilot study in baboons demonstrated that 18F-PBR111 produced 
a robust TSPO-specific, displaceable signal in the brain (Carson et al., 2010).  
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Autoradiography work by our group showed that differences in binding affinity 
between HABs, MABs, LABs were substantial across all the 2nd generation TSPO 
ligands tested  (DAA1106, DPA713, PBR06, PBR111, PBR28), however PBR111, 
together with DAA1106 and DPA713 displayed the smallest difference in affinity 
between HABs and LABs. The in vitro affinity of PBR111 in LABs was 4 fold 
smaller than that in HABs, however our prediction was that the affinity in LABs 
would be still sufficiently high (Ki=62 nM) to yield a measurable signal in vivo.  
The possibility of obtaining measurable signal in LABs differentiates 18F-PBR111 
from another excellent radiotracer, 11C-PBR28, that displays an extremely high in 
vitro affinity to TSPO in HABs (Ki=3 nM), but very low in LABs (Ki=237 nM), 
which is unlikely to be sufficient for in vivo measurements. Taken together, the 
observations from in vitro work led to the prediction that the use in vivo of 18F-
PBR111 would require correction for variation in binding affinity, similarly to that of 
all other 2nd generation radiotracers, and would allow the inclusion of LABs, as well 
as HABs and MABs subjects, in my PET study.  
Our prediction was that 18F-PBR111 would be a more sensitive radiotracer compared 
to the 1st generation TSPO radioligand ¹1C-(R)-PK11195. An analysis by our group, 
using a biomathematical approach based on in vitro data, predicted that the within-
subject variability for 18F-PBR111 would be lower than that of ¹¹C-(R)-PK11195 for 
HABs and MABs in both normal and diseased states (Guo et al., 2012). This implied 
that for between-subject studies may demand smaller sample sizes with 18F-PBR111 
to detect significant differences in TSPO density when binding class information is 
known a priori. At the beginning of the recruitment of participants in my study, it was 
discovered that binding class could be easily identified using a single genetic test 
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from peripheral blood assays, making the stratification of subjects across binding 
affinity classes much simpler. 
A recent study by Mattner and coauthors examined the binding of 18F-PBR111 in 
experimental autoimmune encephalitis (EAE), a rodent model of relapsing-remitting 
MS (Mattner et al., 2013). Combined postmortem histologic analysis and in vivo PET 
imaging with18F-PBR111 revealed an increased radioligand uptake in EAE that co-
localized with markers of activated microglia and macrophages, and paralleled the 
temporal dynamics of their up regulation during experimentally-induced relapses. In 
summary, preclinical evidence strongly indicates that 18F-PBR111 is a suitable PET 
radiotracer for imaging the innate immune response in relapsing-remitting MS 
patients. 
The study presented in this thesis is the first to use 18F-PBR111 in human subjects to 
my knowledge. The safety of 18F-PBR111 administration in human subjects was 
assessed through the evaluation of preclinical dosimetry and toxicology data. 
Dosimetry data were acquired from a study in adult male baboons and extrapolated to 
human application (Verschuer et al., 2012). Based on these data the effective dose of 
18F-PBR111 was estimated at 0.02 mSv/MBq, leading to an exposure of a maximum 
effective dose of approx. 4 mSv yielded by administration of 200 MBq of 18F-
PBR111 for each PET scan per participant. With regard to toxicology data, the 
Australian Nuclear Science and Technology Organization (ANSTO) has investigated 
the safety of PBR111 in an extended single-dose toxicology study in rats and reported 
no toxic or mutagenic effects (ANSTO, Personal Communication). Based on these 
data, and taking into consideration factors such as feasibility of manufacture, safety 
margins and levels which do not produce a pharmacological effect, it was established 
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that the maximum clinical mass dose to be administered in human subjects was 10 µg, 
which was deemed largely sufficient for my PET imaging trials. 
1.5.2 Rationale for the integration of different imaging modalities 
My study combined PET imaging with structural and functional MRI. Subjects 
underwent the MRI scan on the same day as the PET scan. PET imaging suffers from 
limited spatial resolution and lack of the spatial information necessary for precise 
localization of anatomical regions of interest.  In order to allow the quantification of 
PET signal in specific anatomical regions, MRI images are usually acquired in 
conjunction with PET to allow co-registration (see details in Chapter 2) of the MRI as 
an anatomical reference.   
Additionally, the use of structural MRI in patients with MS allows the anatomical 
localization of demyelinating lesions. The typical MRI hallmarks of pathology in MS 
are hyperintense areas observed with T2-weighted FLAIR sequences. Abnormal T2-
signal detected on MRI correspond to MS demyelinating plaques at postmortem 
examination (Stewart et al., 1984). 
 Imaging hallmarks of acute relapsing MS are the Gadolinium-enhancing lesions. T1-
weighted scans using Gadolinium enhancement reflect the presence of local 
disruption of the BBB with concomitant inflammatory mononuclear-cell infiltrates. 
The rational of Gadolinium-enhancement is that Gadolinium-chelates do not cross an 
intact BBB while in the presence of BBB leakage the Gadolinium-chelate enters the 
interstitial CNS compartment.  This will result in an increase of the T1-weighted MRI 
signal relative to that observed with an intact BBB. Based on structural T2-FLAIR 
and post-Gadolinium T1-MRI images, I have assessed the TSPO PET signal both 
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within and outside demyelinating and acutely inflammatory lesions in the white 
matter of MS patients (presented in Chapter 4).  
We have also acquired Magnetization Transfer parameters, in order to better 
characterise inflammatory changes occurring outside lesions. Magnetization Transfer 
contrast represents proton interactions between free fluid and macromolecules, such 
as myelin, and could be used as a marker of ultrastructural brain tissue integrity.  The 
most widely used Magnetization Transfer contrast parameter is the magnetization 
transfer ratio (MTR), representing the percentage reduction of MRI signal when 
applying off-resonance radiofrequency irradiation. The combined use of MTR and 
T2-FLAIR, presented in Chapter 4 of this thesis, aimed to allow the segmentation of 
the white matter in lesional and non-lesional areas (based on T2-FLAIR parameters), 
and the ulterior classification of non lesional-areas into normal and abnormal areas 
(see Chapter 4 for further details). The intensity of 18F-PBR111 PET signal was 
measured and compared across all these MRI-defined regions of interests. 
My study also included the use of functional MRI (fMRI), based on the blood oxygen 
level dependent (BOLD) signal. fMRI gives an indirect measure of neuronal function, 
specifically consisting in aggregate neuronal excitation and inhibition in grey matter 
circuits (Logothetis, 2008). MS lesions may affect the function of neuronal networks 
in several ways: early acute inflammatory responses lead to permanent axonal 
changes (Trapp et al., 1998); furthermore, fMRI studies highlighted an adaptive and 
compensatory role of brain circuit plasticity in response to brain lesions that can limit 
the clinical expression of the disease (Cifelli and Matthews, 2002; Reddy et al., 2000). 
By measuring patterns of spontaneous fluctuations of BOLD signal during resting 
state in the absence of a task, fMRI can be used to inform on the architecture and 
interconnectivity of distributed brain networks, specifically the degree of functional 
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correlation between distant areas. Resting-state functional imaging has the advantage 
of a short acquisition time (i.e. less than 10minutes) therefore the addition of resting-
state fMRI sequences causes only minimal additional discomfort to patients already 
undergoing imaging procedures. Alterations in functional connectivity have been 
identified in MS, as well as in many other diseases, even in the absence of evident 
structural modifications, indicating high sensitivity of the method (Barkhof et al., 
2014). I studied the functional connectivity of the hippocampus using resting-state 
fMRI (see chapter 6), to provide an indirect measure of neuronal function, and 
explore the neuronal mechanisms underlying the association between hippocampal 
neuroinflammation and manifestation of affective symptoms in MS patients. 
1.5.3 Aims of the thesis 
Neuroimaging techniques allows the study of the correlation between brain pathology 
and the manifestation of clinical symptoms, in vivo, in patients with MS. MRI has 
been extensively used and represents the gold standard method for diagnosis, 
assessment of natural course of disease and monitoring of treatment efficacy in MS 
patients. However the abnormalities identified with MRI reflect a wide range of 
underlying neuropathological processes and MRI-based measures explain only a 
modest part of the variability associated with clinical expression of MS. Examples of 
this are the poor correlation between extent of radiological involvement and rate of 
development of disabilities (the clinico-pathological paradox), and the weak 
association between imaging findings and manifestation of non-motor implications of 
MS, such as the development of affective symptomatology.   
Molecular imaging, using PET, is an alternative neuroimaging approach that allows a 
higher pathological specificity, and possibly precision, of the measurement. The first 
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examples of application of molecular imaging, and specifically the use of PET 
imaging to visualize microglia through TSPO targeting radiotracers, yielded 
promising results, although it was recognized that more research was necessary for 
identification of optimal PET radioligands with improved SNR compared to the first 
generation of radiotracers.  
The aim of my PhD research project is to explore the potential of TSPO-targeted PET 
as a tool to visualize in vivo neuroinflammatory processes in MS patients. I selected a 
novel TSPO PET radioligand (18F-PBR111), based on optimal in-vitro characteristics 
and promising preclinical applications, and tested it in a sample of healthy controls 
and patients with relapsing-remitting MS.  
The study presented in the thesis is a pilot investigation and follows three principal 
study objectives, as detailed below. The findings of these analyses are presented 
separately in chapters 3 to 6.  
Objective 1: Characterisation of the uptake of 18F-PBR111 in the brain of healthy 
subjects (Chapter 3): 
We examined the kinetic behavior of the radioligand in the brain and plasma, and 
tested whether it yielded a measurable specific signal in the healthy brain; we 
investigated the effects on 18F-PBR111 signal of age and the genetic 
polymorphism of TSPO gene, rs6971, known to determine the affinity of most 
TSPO radioligands.  
Objective 2: Characterisation of 18F-PBR111 signal in lesional and non-lesional white 
matter in MS patients (Chapter 4):  
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18F-PBR111 uptake was quantified across lesional and non-lesional areas of the 
brain white matter using a segmentation based on structural MRI measures, and 
was compared between MS patients and healthy controls, and across lesional and 
non-lesional white matter areas within MS patients; finally, I examined the 
relationship between rate of development of disability and TSPO signal in MRI-
defined lesions.  
Objective 3: Characterisation of 18F-PBR111 signal in the hippocampus of MS 
patients and its relationship to depressive symptoms and neuronal function (Chapters 
5 and 6): 
I compared 18F-PBR111 uptake in the hippocampus of MS patients to that of 
healthy volunteers, and explored the correlation between hippocampal 18F-
PBR111 signal and depressive symptoms (Chapter 5); in Chapter 6, I analysed 
the relationship between the strength of functional connectivity of the 
hippocampus to the rest of the brain measured with resting-state fMRI, and both 
hippocampal 18F-PBR111 signal and depressive symptoms. 
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Chapter 2. Participants and general methodology  
2.1 Design of the study  
This was an open-label study in patients with relapsing-remitting MS and healthy 
volunteers. All subjects were genotyped for the rs6971 SNP, that determines 
variations in affinity between subjects (HAB, MAB, LAB) for second-generation 
TSPO radioligands (Owen et al., 2012).   
The study took place at Imanova Centre for Imaging Sciences, Hammersmith 
Hospital, London. All participants underwent an MRI scan and an 18F-PBR111 PET 
scan on the same day. Four healthy volunteers and one MS patient (all HABs) 
underwent a second 18F-PBR111 PET scan on the following day in order to evaluate 
the reproducibility of the PET signal (presented in Chapter 4).  
Disability was assessed by an experienced neurologist using the EDSS. The Multiple 
Sclerosis Severity Score (MSSS) was calculated based on EDSS scores and disease 
duration according to Roxburgh et al. (2005).  
The study was approved by the Essex 1 Research Ethics Committee (Ref no. 
11/EE/0026) and the Administration of Radioactive Substances Advisory Committee 
(ARSAC).  All subjects gave written informed consent and were given financial 
compensation for the time spent in their participation in the study.  
2.2 Study subjects 
2.2.1 Healthy volunteers 
Healthy controls were recruited from a database of volunteers. For healthy volunteers, 
exclusion criteria included any medical, neurological, or psychiatric illness at 
	  	  
60 
screening or any concomitant pharmacological treatments. All structural MRI images 
were inspected for unexpected findings of potential clinical significance or features 
that might confound PET co-registration or quantitative analysis by an experienced 
clinical neuroradiologist.   
Twenty-five healthy volunteers in total were studied. Three healthy subjects did not 
have a PET scan, due to the failure of PET radioligand synthesis (n=2) or failure of 
artherial catheterization (n=1). Out of the 22 subjects who completed the PET scan, 
21 were included in the analysis presented in Chapter 3 for the characterisation of 18F-
PBR111 binding (the analysis of one subject’s dataset was completed only after the 
completion of that study). Only 11 healthy volunteers, chosen to match MS patients 
for age and rs6971 genotype, were included in the case-control analysis presented in 
Chapter 4. The whole sample of 22 subjects with available PET data was used for the 
analysis presented in Chapter 5. Only fifteen healthy controls underwent fMRI scan 
and were included in the analysis presented in Chapter 6.  
2.2.2 Multiple Sclerosis patients 
Patients with MS were referred by consultant neurologists. All patients had relapsing-
remitting MS based on neurological history and previous evaluations. No subject 
received steroid treatment in the month before the PET scans and patients receiving 
disease-modifying treatments did not change in treatment for at least 3 months prior 
to scanning.  
Thirteen MS patients were included in total. For two patients, PET data could not be 
analysed due to failure of metabolite analysis. The remaining sample of 11 subjects 
was used for the analysis presented in Chapter 4 and 5. All 13 MS patients’ data were 
used for the fMRI analysis presented in Chapter 6.   
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2.3 Magnetic Resonance Imaging 
Subjects underwent MRI scanning on the same day as PET scanning, approximately 2 
hours before the beginning of the PET scan.  MRI data was acquired on a 3T Siemens 
Verio (Siemens Healthcare, Erlangen Germany) clinical MRI scanner equipped with a 
32-channel phased-array head coil, over a period of 60 minutes. Data acquired 
included T1-weighted scans (with and without Gadolinium), T2-weighted FLAIR, 
MTR, and resting state fMRI data.  
T1-weighted structural images were applied for PET co-registration and used the 
Alzheimer’s Disease Neuroimaging Initiative recommended parameters with a 
parallel imaging factor of 2 in 5m:09s (Jack et al., 2008).  T1-weighted images were 
acquired pre- and post- iv Gadolinium-chelate administration (0.1 mmol/kg Gadoteric 
Acid, Dotarem®). Resting-state fMRI data was acquired with a double-echo gradient 
echo EPI sequence, capturing 150 volumes in 5m:06s. 
Details on specific protocols used for T2-weighted FLAIR images and MTR maps are 
presented in Chapter 4, while the protocol for the resting-state fMRI and functional 
connectivity analysis are presented in detail in Chapter 6.  
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2.4 Positron Emission Tomography 
2.4.1 Radioligand synthesis 
18F-PBR111 was labelled with fluorine-18 by a simple one-step tosyloxy-for-fluorine 
nucleophilic aliphatic substitution, followed by purification by semi-preparative high-
performance liquid chromatography	   (HPLC) and reformulation. The synthetic 
procedure of 18F-PBR111 was adapted from a previously described method (Fookes et 
al., 2008). A fully automated procedure was developed in-house using a Siemens 
Explora GN module coupled with a semi-preparative HPLC system. Figure 2.1 
illustrates the radiosynthesis of 18F-PBR111. 
18F-Fluoride, produced using a Siemens RDS-111 Eclipse cyclotron equipped with a 
fluoride target loaded with oxygen-18 enriched water, was obtained by means of the 
18O(p,n)18F reaction. The 18F-fluoride in solution in oxygen-18 enriched water was 
then trapped onto a DW-TRC-L trap and release cartridge (O.R.T.G.). Following that 
first step the fluoride was released into the reactor using 1.0 mL of a solution 
consisting of 8.3 mL of acetonitrile, 0.8 mL of water, 250 mg of K222 and 50 mg of 
K2CO3. The content of the reactor was evaporated a first time and then the 
evaporation process was repeated 2 times following the addition of 1 mL of 
acetonitrile each time. The toxyloxy precursor (6.0-10.0 mg in solution in 1.0 mL of 
anhydrous acetonitrile) was then added to the reactor containing the “dry” 18F-
fluoride. The reaction mixture was heated for 5 min at 100 ºC and then cooled to 50 
ºC before diluting with water. The crude reaction mixture was then diluted with water 
(3 ml) and loaded onto the HPLC injection loop for purification on an Agilent Eclipse 
XDB C18 column (5 µm, 250 × 9.4 mm) with ammonium formate buffer (pH 
4)/CH3CN (55:45, v/v) at 9.5 mL/min. The fraction containing 18F-PBR111 was 
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collected in water (20 ml) and loaded onto an activated Waters Sep-Pak® Classic C18 
cartridge (Waters Corp.) for reformulation. Following an initial SepPak® column 
wash with water, 18F-PBR111 was eluted off the column with ethanol and 0.9% saline 
solution for injection to lead to 18F-PBR111 formulated in 11 mL of maximum 20% 
(v/v) ethanol in 0.9% saline solution for injection. In the final step a sterile filtration 
through a 0.2 µm sterile filter (Millipore Millex GV, 0.22 µm, 33 mm) was performed 
to deliver the final dose as a sterile and pyrogen-free solution. 
Typically, the total 18F-PBR111 synthesis procedure, including HPLC purification 
and Sep-Pak®-based formulation, was accomplished in less than 60 min.  Up to 4.2 
GBq of 18F-PBR111 (>97% radiochemically pure, n>20) were obtained starting from 
10 GBq of 18F-fluoride with a specific radioactivity of up to 480 GBq/µmol. 
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Figure 2.1 Radiosynthesis of 18F-PBR111 
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2.4.2 PET protocol 
Median injected mass of 18F-PBR111 was 0.33 µg (range 0.16 – 8.66) in healthy 
volunteers and 0.50 µg (range 0.2 – 1.9) in MS patients. 
PET data were reconstructed using filtered back projection including corrections for 
attenuation and scatter (based on a low-dose Computerised Tomography acquisition). 
Dynamic data were binned into 29 frames (durations: 8 x 15 s, 3 x 1 min, 5 x 2 min, 5 
x 5 min, 8 x 10 min).  
Arterial blood data were sampled via the radial artery to enable generation of an 
arterial plasma input function. A continuous sampling system (ABSS Allogg, 
Mariefred, Sweden) was used to measure whole blood activity each second for the 
first 15 minutes of each scan. Discrete blood samples were manually withdrawn at 5, 
10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 110 and 120 minutes after scan start to 
facilitate measurement of whole blood and plasma activity. Samples taken at 5, 10, 15, 
20, 30, 50, 70, 90 and 120 minute time points were also analysed using HPLC to 
determine the fraction of radioactivity corresponding to intact parent compound in 
arterial plasma. The first three discrete blood samples were used to calibrate the 
continuous blood data, and then the continuous and discrete data sets were used to 
form a whole blood activity curve covering the duration of the scan. Discrete plasma 
samples were divided by the corresponding whole blood samples to form plasma-
over-blood (POB) data. A constant POB model was fitted (i.e. average of POB 
values). This POB value was then multiplied by the whole blood curve to generate a 
total plasma curve. Parent fraction data were fitted to a sigmoid model f= ((1-
(t3./(t3+10a)))b+c)/(1+c) where t is time and a, b and c are fitted parameters. The 
resulting fitted parent fraction profile was multiplied by the total plasma curve and 
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then smoothed post-peak using a tri-exponential fit to derive the required parent 
plasma input function. For each scan, a time delay was fitted and applied to the input 
function to account for any temporal delay between blood sample measurement and 
the tomographic measurements of the tissue data. 
2.4.3 Image analysis 
Dynamic PET data were corrected for motion via frame-to-frame image registration 
and aligned with the individual’s structural T1 MRI image using Statistical Parametric 
Mapping-5 (SPM5, Wellcome Trust Center for Neuroimaging, 
http://www.fil.ion.ucl.ac.uk/spm) with a mutual information cost function. 
The Clinical Imaging Center neuroanatomical atlas (Tziortzi et al., 2011) was 
nonlinearly deformed into the individual’s space, via T1-weighted MRI data mapping, 
to obtain a personalized anatomical parcellation of regions of interests. Details on 
Volumes of Interest (VOIs) used for each of the analyses are presented separately in 
each chapter. Each VOI was then applied to the dynamic PET data to derive regional 
TACs.  
2.4.4 Kinetic analysis 
A two-tissue compartment (2TC) kinetic model with a metabolite-corrected plasma 
input function was applied to the dynamic PET data using a fixed blood volume 
correction of 5%. For each VOI examined, the total Volume of Distribution (VT) was 
estimated from the rate constants as described previously (Gunn et al., 2001).  The 
Logan graphical method (Logan et al., 1990) employing a plasma input, using a fixed 
blood volume correction of 5% and a linear start time at 35 minutes was also used to 
estimate the VT of each VOI and further applied at the voxel level to produce 
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parametric VT maps. Model fitting and parameter estimation were performed using 
software implemented in Matlab R2008b (The MathWorks, Inc.). 
The choice and definition of VOIs is explained separately for each analysis in 
Chapters 3 to 6. 
A recent study using 11C-PBR28 in healthy subjects (Rizzo et al., 2014) explored the 
use of an improved quantification model, based on the hypothesis of the existence of 
an additional irreversible component from the blood to the endothelium. The study 
findings suggested that the addition of that irreversible component in the model 
provides some potential advantages in terms of accuracy of measurements. Our study, 
however, is testing the use of 18F-PBR111 for the first time in humans, and since there 
are no available data on the quantification of 18F-PBR111, we prefer to choose the 
application of a simpler 2TC kinetic model that, in our view, relies on fewer 
assumptions and therefore is preferable for a pilot investigation. Since the use of the 
additional irreversible component for kinetic modeling, as suggested by Rizzo et al, 
has not been tested in clinical populations, we feel it is important that its use is first 
applied to patients using a better characterised tracer such as 11C-PBR28, before its 
application to novel tracers.  
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2.5 Statistical analysis 
The statistical analyses used in this thesis include both parametric and non-parametric 
statistical tests. The use of non-parametric statistics, including use of medians and 
ranges for descriptive statistics, non-parametric comparisons for paired and 
independent group comparisons, and Spearman’s tests for correlations, was generally 
preferred considering the small sample size of our study population, and the non-
normal distribution of the variables analysed in our studies. In fact, for smaller studies 
(e.g. with <30 cases), Altman (1999) has recommended use of a non-parametric tests 
to best guard against false positives (Type I error) unless there is confidence that the 
data are normally distributed, which we cannot have in this case. In fact, in our 
analysis of  [18F]-PBR111 PET scans in healthy controls we found that 18F-PBR111 
VT was not normally distributed as demonstrated by visual inspection of data and 
Shapiro-Wilk normality test (White matter VT: p=0.032; n=21), hence we preferred to 
describe the distribution of the VT data using non-parametric statistics, and to use 
non-parametric statistics for comparison of VT data between genetic groups (Chapters 
3 and 4), between cases and controls (Chapter 4), and between VOIs within the same 
subjects. Similarly, we used non-parametric statistical tests for study of correlation 
between VT data and clinical variables (Chapter 4) and for correlations of clinical 
variables to each other (Chapter 5).  However, a possible concern can be that with 
non-parametric statistics Type II error rates (false negatives) might arise.   
Parametric statistics was used in cases where a general linear model approach was 
needed (for example Analysis of Covariance (ANCOVA) in chapters 3 and 5), and for 
Linear Regression and partial correlation analyses, where the independent effects of 
multiple regressors on the variables of interest were studied (Chapters 3 and 5).  
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Chapter 3. Influence on genotype and age on 18F-PBR111 in 
vivo binding signal in healthy volunteers 
3.1 Introduction 
Microglia activation may be used as an index of neuroinflammatory processes in 
imaging studies, hence a method to quantify microglia activation in vivo would 
prove of potential utility as a diagnostic tool or a pharmacodynamic marker in drug 
development.  
PET has the unique ability to quantify microglial density in the human brain non-
invasively, by targeting the TSPO. PK11195, a selective antagonist for the TSPO, 
has been labeled with 11C, and used as PET radioligand for more than 15 years to 
image neuroinflammation (Cagnin et al., 2007). The 11C-(R)-PK11195 signal was 
found to be elevated in a variety of neuroinflammatory brain diseases (Debruyne et 
al., 2003; Edison et al., 2008; Gerhard et al., 2005; Pavese et al., 2006). However, 
the low brain extraction and the poor SNR of 11C-(R)-PK11195 images have led to 
the search for improved TSPO PET imaging agents (see Chapter 1 for further 
details).  
In the past 5 years numerous 2nd generation TSPO ligands have been proposed 
(Chauveau et al., 2008; Endres et al., 2009; Kreisl et al., 2010; Mizrahi et al., 2012). 
Although these ligands were claimed to have increased delivery across the BBB or 
higher SNR over 11C-(R)-PK11195, initial human studies have demonstrated 
considerable variability in their binding across subjects, including the presence of the 
so called “non-binders”, healthy subjects who demonstrated very little if any binding 
of 11C-PBR28 (Kreisl et al., 2010). All 2nd generation ligands tested in vitro in human 
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tissue samples bind TSPO with either high affinity or low affinity or a mix of high 
and low affinity binding sites (HABs, MABs, LABs) (Owen et al., 2011; Owen et al., 
2010). This finding has retrospectively explained the ‘non-binders’ phenomenon, as 
the affinity of 11C-PBR28 to LABs was only 188 nM (Owen et al., 2010), and thus no 
specific binding in these subjects would be expected. The presence of MABs in the 
population also explained the variability in the PET signal across healthy volunteers, 
as these subjects may be expected to have significantly lower binding of the 2nd 
generation ligands, from HABs. Our group has demonstrated that these different 
binding patterns in humans are fully explained by the rs6971 polymorphism in the 
TSPO gene (Owen et al., 2012). The frequencies of this polymorphism vary across 
ethnic groups with the Caucasians having the highest frequency for LABs 
(HABs:MABs:LABs=49:42:9) compared to African Americans (56:38:6)  and Han 
Chinese and Japanese (94:6:0.001).  Our hypothesis that the rs6971 polymorphism 
explained the large between subject variability seen with 2nd generation TSPO PET 
ligands, was consistent with in vivo data showing differences between HAB and MAB 
binding for TSPO ligands, 18F-FEPPA and 11C-PBR28 (Kreisl et al., 2013a; Mizrahi 
et al., 2012).  
 18F-PBR111 was previously evaluated in vivo in the non-human primate brain, 
which demonstrated high delivery, fast kinetics and high SNR (BPND~4), based on 
the blockade of the 18F-PBR111 binding with unlabeled PK11195 (7 mg/kg i.v.) 
(Carson et al., 2010). An in silico biomathematical model predicting the in vivo 
performance of radioligands in humans (Guo et al., 2009), enabled us to account for 
the influence of genetic polymorphisms in the target protein.  The model predicted 
that 18F-PBR111 would show moderate to high specific binding in the healthy 
human brain across genetic groups (Guo et al., 2012). Evidence of the ubiquitous 
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expression of TSPO throughout the brain (Chen et al., 2004b) and the global 
reduction in 18F-PBR111 binding following the administration of unlabeled 
PK11195 in the non-human primate (Carson et al., 2010), indicated that any 
reference region approach will be confounded by a contribution from specific 
binding. 
Here the characterisation of 18F-PBR111 binding in healthy human volunteers is 
presented. I test the hypothesis that in vivo, the 18F-PBR111 signal is dependent on 
the rs6971 polymorphism in the TSPO gene, and evaluate the effects of age on 
binding in the human brain. 
 
 
  
	  	  
72 
3.2 Methods 
3.2.1 Subjects 
In total, 21 healthy volunteers, aged between 28 and 62 years (51 ± 10 yrs, 14 females, 
7 males) with an average body weight of 77.2 ± 22.4 kg, were included in the current 
analysis.  
3.2.2 Definition of Volumes of Interest 
Our attention focused on regions of moderate and high binding based on previous 
literature (Fujita et al., 2008): brain stem, thalamus, hippocampus, global cortical 
regions, cerebellum, and caudate. The latter was chosen as representative of low 
binding regions. Due to defluorination of the metabolite from 18F-PBR111 (Fookes et 
al., 2008), VOIs for frontal, parietal, occipital, temporal cortex and cerebellum were 
eroded of 5 mm away from the skull to avoid spill in from uptake outside the brain 
(Carson et al., 2003). Each VOI was then applied to the dynamic PET data to derive 
regional TACs. 
3.2.3 Kinetic analysis 
The total VT was estimated using a 2TC kinetic model with a metabolite-corrected 
plasma input function (Gunn et al., 2001)  and with  the Logan graphical method 
(Logan et al., 1990) (details presented in Chapter 2).  
In order to account for free fraction in plasma (fp), the VT/fp was obtained in addition 
to VT, to consider correction for plasma protein binding effects across subjects. VT 
and VT/fp were compared with the averaged standardized uptake value from 90 to 120 
min (SUV90_120 min).  
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To investigate the scanning duration required for reproducible estimates of VT, time 
stability analysis was performed by analysing scan durations ranging from 30 to 120 
min., in 10 min. increments.  
3.2.4 Statistical analysis 
The Mann-Whitney U and Kruskal-Wallis Tests for independent samples were used 
to evaluate the difference in VT between the different genetic groups. Linear 
regression and Analysis of Covariance (ANCOVA) were used to characterize 
respectively the effect of age on VT within each genetic group, and the effect of age 
on the difference in VT between the different genetic groups.  
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3.3 Results 
3.3.1 Plasma and kinetic analysis 
In plasma, the concentration of 18F-PBR111 peaked at about 1 min. followed by a 
rapid decrease, which was well described by a tri-exponential model (Figure 3.1A). 
One metabolite appeared quickly following parent administration. The parent 
compound accounted for about 40% of the total concentration in plasma at 30 min., 
and the parent fraction further reduced and reached between 9.3% to 36.4% (20.1% ± 
8.7%) at 120 min (Figure 3.1B). The metabolite has been previously identified as a 3-
18F-fluoropropionic acid, which is more polar than the parent compound (Fookes et 
al., 2008). A bone uptake activity was observed and was consistent with 
defluorination reported for this metabolite in the literature (Fookes et al., 2008).  The 
metabolite profile did not vary across genetic groups. The fp was measured for 8 
HABs (0.05 ± 0.02), 6 MABs (0.07 ± 0.02) and 4 LABs (0.06 ± 0.01). No significant 
difference was found in fp across the different genetic groups (Figure 3.2).  
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Figure 3.1 Measurements of radiotracer concentrations and parent fraction 
in the plasma 
(A) 18F-PBR111 plasma concentration fitted with a triexponential model after peak, in 
a representative subject with High Affinity Binding (HAB) status; (B) Concentration 
of the plasma parent fraction of 18F-PBR111 fitted with a sigmoid parent fraction 
model, in a representative subject with HAB status. 
  
A 
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Figure 3.2  Plasma free fraction (fp) for different genetic groups: HABs, 
MABs, and LABs 
The figure illustrates the mean concentration estimates of plasma free fraction (fp) of 
18F-PBR111 across each binding status group. No significant difference was found 
between groups. HAB: High Affinity Binder; MAB: Mixed Affinity Binder; LAB: 
Low Affinity Binder. 
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After injection, 18F-PBR111 readily entered the brain. The distribution of the 
radioactivity within the brain was widespread, with slightly higher signal in thalamus, 
brain stem, hippocampus, followed by other cortical regions, cerebellum and lowest 
in striatum, consistent with previous findings with 11C-PBR28 (Figure 3.3) (Fujita et 
al., 2008).  
The concentration of the ligand in tissue peaked at around 2 min. after injection for all 
subjects and washed out with different elimination rates corresponding to the different 
genetic groups (Figure 3.4). In HABs, the concentration in a high binding region such 
as brain stem, decreased to 50% of the peak at 60 min. whilst in MABs and LABs, the 
washout was faster and the concentration decreased to 50% of the peak at 40 min. and 
20 min. respectively.   
2TC fits to the TACs across VOIs in a representative HAB subject are shown in 
Figure 3.5A.  The time stability analysis of the 2TC model demonstrated an increase 
in VT extending beyond the 120 min. scan duration used in our studies (Figure 3.5B). 
This effect was present in all brain regions and for all genetic groups. A duration of 
scan of 60 min. would lead to 10% to 20% underestimation of VT in comparison to a 
value obtained from the full 120 min. acquisition.  
3.3.2 Genetic influence on the in vivo binding signal 
The comparison of the SUV60_90min, VT and VT/fp values in grey matter masked 
regions of interest across different genetic groups is presented in Figure 3.6. Although 
we observed a between-groups difference for all three parameters, SUV90_120min didn’t 
reach significance whilst we observed significant differences for VT between all 
groups (HABs vs MABs: p=0.025; HABs vs LABs: p=0.005 and MABs vs LABs: 
p=0.014). The correction for plasma free fraction (VT/fp) did not reduce the between 
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subjects variability. Significant differences were found for VT/fp between HABs and 
both MABs and LABs across all regions, but between MABs and LABs were only 
seen in the hippocampus and brain stem. For these reasons, only the VT will be 
reported in the following analyses of this chapter. The average absolute difference in 
VT between HABs and MABs (1.54 ± 0.23) was similar to the one observed between 
MABs and LABs (1.14 ± 0.17), in line with the hypothesis that MABs express half of 
the high affinity sites and half of the low affinity sites.  
A spatially normalised averaged VT parametric map for each genetic group is 
presented in Figure 3.3, illustrating the global difference in VT across the different 
genetic groups consistent with the results from the VOI analysis. 
 
  
	  	  
79 
 
 
Figure 3.3 Spatially normalised average 18F-PBR111 VT parametric maps for 
each genetic group. 
The figure displays the spatially normalised averaged voxel-wise 18F-PBR111 VT 
parametric maps for each binding group, illustrating the global difference in 18F-
PBR111 VT between the different groups. HAB: High Affinity Binder; MAB: Mixed 
Affinity Binder; LAB: Low Affinity Binder. 
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Figure 3.4 Averaged time–activity curves in brain stem and caudate across 
genetic groups 
The figure illustrates the averaged time-activity curves (TACs) for 18F-PBR111 across 
TSPO binding groups. Brainstem and Caudate are displayed as representative VOIs 
with relatively high and low TSPO binding, respectively. HAB: High Affinity Binder; 
MAB: Mixed Affinity Binder; LAB: Low Affinity Binder. The Error bar represents 
the Standard Deviation (SD) at each frame. 
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Figure 3.5 Kinetic model fits to HAB time–activity curves and time-stability 
analysis 
The figure illustrates the fits of the 2 Tissue Compartment (2TC) model to the 18F-
PBR111 Time Activity Curves (TACs) across various Volumes of Interests (VOIs) in 
a representative High Affinity Binder subject. (A) Unconstrained 2 Tissue 
Compartment model fit to time–activity curves. (B) Assessment of time-stability of 
18F-PBR111 VT for unconstrained 2TC model. The time stability analysis of the 2TC 
model demonstrated an increase in VT extending beyond the 120 min. scan duration 
used in our studies. This effect was present in all brain regions and for all genetic 
groups. 
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Figure 3.6 Comparison of SUV90_120 min, VT, and VT/fp values between genetic 
groups across VOIs 
The figure illustrates 18F-PBR111 Standard Uptake Values (SUV), Volume of 
Distribution (VT), and Volume of Distribution corrected for plasma free fraction 
(VT/fp) across TSPO binding groups, and across Volumes of Interest (VOIs). HAB: 
High Affinity Binder; MAB: Mixed Affinity Binder; LAB: Low Affinity Binder. 
Horizontal lines indicate mean values for each genetic group. 
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3.3.3 Relationship with age 
A substantial variability in VT was still found within each genetic group, especially in 
HABs. We found a significant correlation between age and VT in all VOIs except 
caudate for HABs, and in the brainstem, hippocampus, and cerebellum for MABs. 
The linear regression slope in HABs was 0.09, and was about 2-fold higher than the 
slope estimated for MABs (0.04), suggesting that the effect of age is more evident in 
subjects with higher specific binding (Figure 3.7). The relationship between VT and 
age was not studied in LABs because of the small sample size (n=4) and limited age 
range of participants (44-56 years old). When ANCOVA was used to correct for the 
age effect within each binding class, the standard error of the mean in HABs was 
reduced by 40%.  
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Figure 3.7 Correlations between VT and age in HABs and MABs across the 
different VOIs 
Pearson’s coefficients and significance across the different VOIs: Brain Stem, HAB: 
r=0.68, p<0.05, MAB: r=0.78, p<0.05. Thalamus, HAB: r=0.73, p<0.05; MAB: 
r=0.57, Non Significant (N.S.). Cortical regions, HAB: r=0.67, p<0.05; MAB: r=0.61, 
N.S. Cerebellum, HAB: r=0.70, p<0.05; MAB: r=0.81, p<0.05. Caudate, HAB: 
r=0.55, N.S., MAB: r=0.37, N.S. Hippocampus, HAB: r=0.73, p<0.05; MAB: r=0.74, 
p<0.05.  
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3.4 Discussion 
The binding of 18F-PBR111 in the healthy human brain was characterised. Our team 
previously identified a strong effect of the rs6971 polymorphism in the TSPO gene on 
the binding affinity of PBR111 to TSPO in human tissue in vitro (Owen et al., 2011). 
Here, we observed the same effects of the rs6971 polymorphism on the in vivo 
binding of 18F-PBR111, in line with the prediction based on the genetic status of the 
subjects.   
The distribution of the signal yielded by 18F-PBR111 was similar to that of other 
TSPO tracers previously evaluated in humans, such as 11C-R-PK11195 and 11C-
PBR28.  
The 2TC kinetic model fitted the time activity curves well except for a slight 
underestimation of the tail. This observation agrees with the interpretation of the time 
stability analysis which shows that VT increases with scan duration.  This could be 
due to some small irreversible component, with radiometabolite getting into the brain 
being a possibility. A similar observation has been made with other 2nd generation 
TSPO tracers, such as 11C-PBR28, 11C-DPA713 and 18F-PBR06 in humans (Endres et 
al., 2009; Fujimura et al., 2009; Fujita et al., 2008).   
Another potential explanation for this observation is the presence of binding of TSPO 
to endothelial cells. Previous studies, using both 11C-R-PK11195 and 11C-PBR28, 
demonstrated that the additional inclusion of a vascular component in the kinetic 
model might provide more precision in the quantification of TSPO specific signal 
(Rizzo et al., 2014; Turkheimer et al., 2007). Furthermore, due to the particularly high 
TSPO density in the vascular endothelium, a concentration gradient is likely to occur 
through the brain parenchyma, where the ligand binds non-specifically to lipids on its 
	  	  
86 
way to the binding sites. It is possible that with high lipophilicity tracers (e.g. with 
11C-PBR28), the concentration of the free tracer at the binding site may be lower than 
its average tissue concentration, leading to decreased in-vivo affinity of the tracer to 
TSPO. This provides some support to the hypothesis that similarly to 11C-PBR28, the 
high affinity binding of 18F-PBR111 to the endothelial TSPO might be responsible of 
the observed underestimation of the data with the 2TC model we used. 
As the increase in VT of 18F-PBR111 was global, as with other tracers, the scan can 
likely be shortened to 60 min allowing for a consistent underestimation of less than 
20%. However, when comparing different groups, analysis should always be 
performed with the data from the same scan durations and the degree of 
underestimation in different clinical populations needs to be evaluated. 
We compared 18F-PBR111 binding across genetic groups using three outcome 
measures, namely SUV60_90min, VT and VT/fp. Significant differences, consistent with 
our predictions based on in vitro data were observed between HABs, MABs and 
LABs using both VT and VT/fp, but not using SUVs.  In our data, fp did not differ 
across genetic groups in the healthy subjects and the variability between subjects in 
VT was not reduced after correction for the free fraction in plasma. Therefore, VT 
estimated from a 2TC model appeared to be the most appropriate measure to quantify 
the total binding of TSPO. 
Within each genetic group, there was still variability in VT across subjects, especially 
in HABs. We found that this variability could be partly explained by a correlation 
between age and binding. 
Our observation of an association between age and TSPO density is consistent with 
the results of some previous human imaging studies (Gulyas et al., 2009), although 
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not consistently observed using other radiotracers (Suridjan et al., 2014), and is 
further supported by preclinical data indicating a progressively increased TSPO 
density in aging rats using serial longitudinal microPET assessments (Walker et al., 
2015).   These observations are line with the notion of increased microglia activation 
associated with aging (Ogura et al., 1994), an association that appear to vary across 
brain regions (Hart et al., 2012).  
By using ANCOVA to correct for the effect of age, the standard error of the mean VT 
for HABs was reduced by 40%. Thus age effect should be considered carefully in 
TSPO study design by either carefully matching subjects for age or by applying an 
appropriate correction for age related changes. Although the relationship between VT 
and age across the full age range is unlikely to be linear, a linear regression was used 
as a first order approximation. We found the slope of HABs was about 2-fold higher 
than that seen for MABs, which is consistent with the previously measured affinity 
ratio between high and low binding sites in vitro. 
We additionally observed regional differences in 18F-PBR111 binding suggesting that 
microglia density is not homogenous across the healthy human brain. Our findings are 
in line with earlier post-mortem observations (Mittelbronn et al., 2001). 
Finally, the fluorine-18 radionuclide provides advantage for use of the radioligand in 
multicenter clinical trials, however the approach we used for quantification requires 
arterial input methods, which would limit its use to centers with adequate 
infrastructure and expertise. In addition, there is an element of defluorination present, 
and care should be taken when evaluating most superficial cortical layers close to 
bone. 
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In conclusion, 18F-PBR111 PET showed a measurable and quantifiable specific signal 
in the healthy human brain for TSPO.  A proportion of the inter-subject variability in 
the PET signal for healthy volunteers can be attributed to the genetic variation at the 
rs6971 locus and age of the subjects. Having accounted for these effects, the ligand 
can be used for the quantitative assessment of TSPO expression related to 
neuroinflammatory process in the brain.  
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Chapter 4. Assessment of white matter inflammation in 
Multiple Sclerosis patients with 18F-PBR111 
4.1 Introduction 
A prominent neuropathological feature of MS is the activation of microglia, resident 
brain innate immune response cells, in the white matter particularly within 
demyelinating lesions, but also extending into adjacent white matter tissue 
(Henderson et al., 2009; Kutzelnigg et al., 2005; Marik et al., 2007; van Horssen et 
al., 2012).  
MRI markers specifically associated with microglial and macrophage activation are 
limited. Correlational post-mortem neuropathology and MRI in MS have confirmed 
that T1-weighted Gadolinium contrast enhancement and associated T2-weighted 
hyperintensity changes in white matter reflect the adaptive immune response, but do 
not specifically inform on relative macrophage or microglial involvement (De Groot 
et al., 2001). T2-weighted white matter hyperintensities also are non-specifically 
associated with other pathological features including demyelination, axonal loss and 
astrogliosis (Gouw et al., 2011). A recent study found that subtle reductions in the 
MRI MTR in peri-lesional white matter volumes are associated with increased 
microglia density (Moll et al., 2011). However, decreases in MTR reflect other 
changes in tissue microstructure, such as demyelination, as well and do not provide a 
specific biomarker for innate immune activation. 
PET radioligand binding to TSPO in brains of patients with MS primarily reflects 
activated microglia and macrophages (Banati et al., 2000; Cosenza-Nashat et al., 
2009). However, the interpretation of the findings of early studies, using the first 
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generation PET tracer 11C-(R)-PK11195, is limited by the rather poor SNR for this 
tracer and non-specific binding, which challenge accurate quantitation of the signal 
(Banati et al., 2000; Debruyne et al., 2003; Vas et al., 2008; Vowinckel et al., 1997).  
A number of second generation TSPO PET radioligands with improved SNR relative 
to 11C-(R)-PK11195, have been developed (Chauveau et al., 2008). Unexpectedly, the 
first two studies using newer TSPO radioligands did not report increases in white 
matter binding of MS patients relative to healthy controls (Oh et al., 2011; Takano et 
al., 2013). However, the analyses did not take into consideration the population 
variation in binding of radioligands associated with the rs6971 TSPO gene SNP 
(Owen et al., 2012).  Heterogeneity of binding across carriers of different alleles may 
have contributed to the failure to differentiate brain TSPO radioligand binding 
between MS patients and healthy controls successfully.  
 18F-PBR111 is a 2nd generation TSPO ligand with promising imaging characteristics 
(Fookes et al., 2008). A recent study showed increased 18F-PBR111 uptake 
corresponding specifically to activated microglia in EAE (Mattner et al., 2013).  We 
have developed a robust approach for quantitative in vivo assessment of specific 18F-
PBR111 binding to TSPO (see previous chapter) (Guo et al., 2013).  
Here, I have used 18F-PBR111 PET co-registered with MRI to evaluate regional 
binding to white matter in healthy volunteers and in MS patients who were stratified 
genetically according to the rs6971 SNP. Based on post-mortem descriptions of 
activated microglia and macrophage distributions (Filippi et al., 2012; Henderson et 
al., 2009; Moll et al., 2011), I predicted increased 18F-PBR111 binding in regions of 
T2-hyperintense lesions, in the immediate peri-lesional volumes, and in non-lesional 
volumes with reduced MTR, compared to that in the white matter of healthy 
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volunteers and in the white matter with a normal MTR (“normal appearing”) in MS 
patients. The reproducibility of 18F-PBR111 signal also was assessed in five subjects 
(four healthy volunteers and one MS patient). 
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4.2 Methods 
4.2.1 Subjects 
The sample included patients with relapsing-remitting MS and age-matched healthy 
volunteers (n=11 per group). All subjects were genotyped for the rs6971 SNP, that 
determines variations in affinity between subjects (who express either a high affinity 
(HAB) or low affinity (LAB) or co-expression of both binding states  (MAB)) for 
second-generation TSPO radioligands (Owen et al., 2012).  Patients with MS and 
healthy volunteers were matched for the rs6971 SNP. The demographic variables, 
TSPO binding affinity class, and clinical characteristics of study participants are 
presented in Table 4.1. 
Focal, non-specific alterations in the white matter signal intensity were found in one 
healthy volunteer and the subject was referred for further evaluation.  This volunteer 
had no past or present neurological symptoms and the physical and neurological 
examination was unremarkable. No other abnormalities were found. The 
neuroradiologist did not judge the findings to be clinically significant or to suggest 
pathology. This subject has been included in the analysis.  Another healthy volunteer, 
who underwent two scans in consecutive days to assess 18F-PBR111 PET 
reproducibility, had diffuse white matter hyperintensities at MRI that were deemed 
compatible with the presence of cerebral small vessel disease.  The subject was 
excluded from the between groups (MS vs. healthy controls) analyses, but was 
included in the analysis of the test-retest reproducibility of the signal.  
In one MS patient (4.1, case 7) I found 2 Gadolinium-enhancing lesions on T1-
weighted MRI. No contrast enhancement was found in any of the other patients.  
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4.2.2 Study design 
 
Each participant underwent an MRI scan and a 18F-PBR111 PET scan on the same 
day. Four healthy volunteers and one MS patient (all HABs) underwent a second 18F-
PBR111 PET scan on the following day in order to evaluate the reproducibility of the 
PET signal.  
Disability was assessed by an experienced neurologist using the EDSS. The MSSS 
was calculated based on EDSS scores and disease duration according to Roxburgh et 
al. (2005). The EDSS and MSSS scores of one patient were not considered in the 
analysis as most disability for the patient had been attributed previously to an 
incomplete traumatic spinal cord injury causing weakness in lower limbs, which was 
antecedent to the onset of MS. 
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 Healthy Volunteersa Relapsing-Remitting MS patients 
Case binding 
affinity 
class 
Age Gender binding 
affinity 
class 
Age Gender EDSS Disease 
Duration 
MSSS DMT 
1 HAB 52 F HAB 48 F - 8 - natalizumab 
2 LAB 51 M LAB 39 F 4 20 3.0 interferon β  
3 HAB 42 F HAB 40 F 4 11 4.9 natalizumab 
4 HAB 59 M HAB 55 F 2 20 0.9 interferon β  
5 LAB 65 M LAB 53 F 7 20 7.4 - 
6 MAB 57 M MAB 59 F 3 16 2.6 interferon β  
7 HABb 28 M HAB 41 F 2.5 14 2.3 - 
8 HABb 28 M HABb 28 M 2 7 3.2 - 
9 MAB 36 F MAB 41 F 6 4 9.1 interferon β  
10 HAB 33 F HAB 42 F 6 1.5 9.6 interferon β  
11 HABb 52 F HAB 50 F 4 2 8.6 interferon β  
Mean age 45.7 years  45.1 years     
Table 4.1 Demographic variables, TSPO binding affinity class, and clinical 
characteristics of study participants 
EDSS: Expanded Disability Status Scale; MSSS: Multiple Sclerosis Severity Score; 
DMT: Disease Modifying Treatment; HAB: High Affinity Binder; MAB: Mixed 
Affinity Binder; LAB: Low Affinity Binder.  
a a twelfth  healthy volunteer, (genotype, HAB; age: 50 y.; gender: female) was 
included in the test-retest analysis but was excluded from the comparison between-
groups due to white matter abnormalities consistent with presence of cerebral small 
vessel disease (see Subjects section). b These subjects underwent two scans in 
consecutive days to assess test-retest reproducibility. 
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4.2.3 MRI  
 
The general characteristics of the MRI scanner and the T1-weighted protocol (with 
and without contrast) have been presented in Chapter 2.  
Volumetric T2-weighted FLAIR images were acquired using a 1mm isotropic 
resolution 3D SPACE sequence (Mugler and Brookeman, 2003), with a 
250x250x160mm FOV, TE=395ms, TR=5s, TI=1800ms, turbo factor of 141,  
256x256x160 matrix, and parallel imaging factor of 2 in 5m:52s.  MTR maps were 
acquired using a 3D spoiled gradient echo sequence [fast low angle shot (FLASH)].  
Two volumes with 1mm isotropic resolution were acquired using 256x240x192mm 
FOV, TR of 27ms and a flip angle of 5° to give pseudo proton density weighting 
(PDw), a parallel imaging factor of 2, 6 echoes acquired using 630Hz/pixel bandwidth 
with TEs every 1.95ms from 1.95 to 11.7ms in 7m:20s.  Each high-bandwidth echo 
was summed to increase SNR without introducing off-resonance effects of low 
readout bandwidth (Helms and Dechent). One volume used a 12.24ms duration 
Gaussian RF pulse at 2.2 kHz off resonance with a nominal flip angle of 540° to add 
magnetization transfer weighting (MTw). MTR maps were calculated using the 
signals from the MTw and PDw acquisitions by the equation:  
         [1] 
4.2.4 PET  
 
Details on radioligand synthesis and PET protocol have been provided in Chapter 2. 
The injected activity was similar in healthy volunteers and MS patients (164.6 MBq ± 
9 and 169.7 MBq ± 12.4 [mean ± SD], respectively).  
PDwMTwPDw SSSMTR /)(100 −⋅=
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In three cases (Table 4.1, cases n. 2, 3, 11), patients were not able to tolerate the 
whole duration of the scan due to increased discomfort related to neurological 
symptoms (i.e. muscular spasms and pain). In these cases I considered the VT 
obtained from the analysis of the first 70 minutes of dynamic acquisition post 
injection. However, this is likely to lead to underestimation of VT for these cases, as 
demonstrated by our previous analysis of time stability of VT (Guo et al., 2013). 
Within subject comparisons of VT obtained with acquisitions of 70 minutes vs 120 
minutes in my sample indicated that scan duration of 70 min would lead to 7 to 35 % 
(median 16%) underestimation of VT in comparison to values obtained from the full 
120min acquisition. On the basis of these data, I applied a correction to the VT of the 3 
patients who could not complete the scan, increasing their VT values of 16%.  
4.2.5 Definition of Volumes of Interest 
 
In healthy volunteers and MS patients, the whole white matter was segmented 
automatically from each individual’s structural T1 MRI image using SPM5 
(Wellcome Trust Center for Neuroimaging, http://www.fil.ion.ucl.ac.uk/spm).  
To define demyelinating lesions in MS patients’ brains, T2-FLAIR hyperintense 
white matter volumes were segmented using JIM version 6.0 (Xinapse Systems, 
Northants) by an experienced MRI analyst (Figure 4.1 a, b).  The white matter of 
patients, segmented using SPM5, was filled with T2-FLAIR lesions to complete the 
whole white matter mask. 
The remaining white matter in the MS patients (remaining after exclusion of the T2-
FLAIR hyperintense lesions, Figure 4.1b) was further segmented to three VOIs as 
follows:  
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- perilesional volumes, including voxels within a 6 mm-thick volume disposed 
around T2-hyperintense lesions (Figure 4.1c);  
- non-lesional low MTR (NLLM) voxels, with MTR ranging between 90-98% 
of the non-lesional mean white matter MTR (Moll et al., 2011) (Figure 4.1d);  
- non-lesional high MTR (NLHM) voxels, showing MTR ≥ 98% of the non-
lesional mean white matter MTR (Figure 4.1e); the NLHM VOI was assumed 
to be representative of the normal white matter tissue (Moll et al., 2011). 
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Figure 4.1 Definition of Volumes of Interest  
a) T2-FLAIR image of a representative MS patient (case 1, Table 4.1); hyperintense 
areas correspond to demyelinating lesions; b) Lesions (dark blue); c) perilesional 
areas (light blue) corresponding to the intersection of 6 mm diameter sphere traced 
around lesions within the image plane; d) Non-lesional voxels with MTR values 
ranging between 90-98% of the mean MTR of non lesional white matter tissue 
(NLLM)  (copper); e) Non-lesional voxels with MTR values ranging above 98% of 
the mean MTR of non lesional white matter tissue (NLHM), corresponding to normal 
appearing white matter (red). 
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4.2.6 Image analysis 
 
Details on image analysis and kinetic analysis have been provided in Chapter 2. As 
previously described, the VT was quantified using 2TC kinetic model with a 
metabolite-corrected plasma input function. The Logan graphical method employing a 
plasma input (Logan et al., 1990) was applied at the voxel level to produce parametric 
VT maps (see Chapter 2 for further details).  
4.2.7 Statistical analysis 
All analyses were conducted using SPSS 20. I expressed 18F-PBR111 VT for the 
whole white matter as V!!". For each subject the mean 18F-PBR111 VT uptake of all 
lesions larger than 100 voxels (V!!) and perilesional volumes (V!!"), respectively, was 
computed. Uptakes of 18F-PBR111 in NLLM and NLHM were expressed as   V!!""# 
and    V!!"#$, respectively.  
Between-subjects comparisons. 18F-PBR111 V!!" was compared between binding 
affinity classes (HABs, MABs, LABs) by using non-parametric comparison for 
independent samples (Kruskal-Wallis Test). I compared 18F-PBR111   V!!" of MS 
patients to that of healthy controls by using a two-tailed Wilcoxon Signed-Rank Test. 
Healthy volunteers’ 18F-PBR111 V!!" was compared to each of MS patients’ VOI 
(  V!!,   V!!",   V!!""#,   V!!"#$) separately using two-tailed Wilcoxon Signed-Rank Tests. 
For those subjects (four healthy volunteers, and one MS patient) who underwent two 
scans in consecutive days, the mean 18F-PBR111 VT of the two visits for all VOIs 
have been used in all between- and within- subject analyses. 
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Within-subjects comparisons. Within MS patients,   V!!,   V!!",   and  V!!""#  were 
separately compared to   V!!"#$, by using two-tailed Wilcoxon Signed-Rank Tests. 
Significance for all tests was set at 0.05. 
The relative increase (Δ) in 18F-PBR111 uptake in lesions, perilesional, and NLLM 
volumes vs NLHM, was computed as follows: 
ΔL= (  V!! -   V!!"#$)/ V!!"#$ 
ΔPL= (  V!!" -   V!!"#$)/V!!"#$  
ΔNLLM=   (  V!!""# -   V!!"#$)/V!!"#$  
Correlations with clinical measures. The relationship between   V!!" and disease 
duration was studied by means of Spearman’s partial rank correlation. The partial 
rank correlation (ρ) coefficient was computed while correcting for the effect of age. I 
explored the relationship between disease severity and relative increase in TSPO 
density within demyelinating lesions, by studying the Spearman’s rank coefficient of 
correlation (ρ) between MSSS score and ΔL. For this analysis, I considered all T2-
FLAIR lesions for each patient as a single VOI.    
Partial Volume Correction. In order to estimate the partial volume effect on the 
outcome measure VT, a voxel-region based algorithm for Partial Volume Correction 
(PVC), consisting in Local Regression Analysis (LoReAn) (Coello et al., 2013), has 
been applied as an exploratory tool to the PET brain volumes of one MS patient (case 
9, Table 4.1). 18F-PBR111 VT was estimated after PVC in the two largest lesional 
volumes and related perilesions, as well as in the NLHM white matter area of the 
same patient.  
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The variability across individual lesions, within each MS patient, was expressed using 
the coefficient of variation (CV) in  V!! across individual lesions, as follows:  
CV=  Standard Deviation(V!!)/Mean(V!!) 
Test-retest variability of   V!!"  was studied in four healthy volunteers and one MS 
patient, and was expressed as the absolute difference between the two consecutive 
days scans divided by the mean of the two scans. For the MS patient who was studied 
twice in consecutive days, I assessed test-retest variability of individual   V!! and   V!!". 
Additionally, I calculated test-retest variability of individual normalised lesional and 
perilesional Distribution Volume Ratio (DVR) by normalising the corresponding VT 
values by   V!!"#$. The DVR was computed as follows: 
DVRL = V!!/  V!!"#$ 
DVRPL = V!!"/  V!!"#$ 
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4.3 Results 
The demographic and clinical characteristics of study participants are presented in 
Table 4.1.  MS patients (10 F, 1 M) and healthy controls (5 F, 6 M) were matched for 
genotype (7 HABs, 2 MABs, and 2 LABs in each group) and had similar age 
distributions [healthy controls, 51 years (28 – 65); (median (range)) and MS patients, 
42 years (28 – 59); Wilcoxon Rank p=0.80].  
4.3.1 Between Subjects contrasts 
A significant effect of TSPO genotype on white matter binding of 18F-PBR111 was 
observed for the whole population [V!!", HABs 3.53 (2.12 – 5.40) (median (range));  
MAB 3.00 (2.50 – 4.43);  and LAB 1.47 (1.18-1.70);  Kruskal-Wallis p<0.01]. 
Whole white matter:  a trend towards lower whole white matter binding was found 
in healthy controls compared to MS patients [V!!", healthy controls 2.50 (1.18 – 
5.23); MS patients 3.53 (1.62 – 4.55); Wilcoxon Rank p=0.06] (Figure 4.2). In MS 
patients, the V!!"correlated with disease duration in HABs (Figure 4.3) (Spearman’s 
ρ=0.86; p=0.03, corrected for age).  The relationship between   V!!"  and disease 
duration was not assessed in the MAB and LAB groups separately, as each of these 
groups had only 2 subjects per group. 
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Figure 4.2 18F-PBR111 uptake in the whole white matter 
18F-PBR111 VT in the whole white matter of MS patients and genotype- and age- 
matched healthy control subjects. The line in the middle of the boxes are median 
values, while the hinges represent the 25th and the 75th percentile respectively. 
Whiskers represent the maximum and minimum values. The contrast between MS 
patients and healthy controls showed a trend for higher 18F-PBR111   V!!" in MS 
patients (Wilcoxon Rank p=0.062 ).  
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Figure 4.3  Relationship between 18F-PBR111 uptake in the whole white matter 
and disease duration 
Relationship between whole white matter 18F-PBR111 VT and disease duration in MS 
patients for patients with different rs6971 genotypes (Spearman’s partial correlation 
in HABs: ρ=0.86; p=0.03, corrected for age). 
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MRI Segmentation-Based VOIs. One hundred sixty-three T2-FLAIR lesions were 
identified in the patients [median total lesion volume per patient, 12708 mm3 (range, 
392-32672 mm3)]. 96/163 individual lesions were larger than 100 voxels in volume 
(median number of lesions larger than 100 voxels per patient, 8; range, 1-17).   
Both   V!! (median, 3.88; range, 1.44 – 5.50) and   V!!" (median, 3.61; range: 1.59 – 
4.66) were greater than the V!!"  V!!" from healthy controls (median, 2.50; range, 1.18 
– 5.23; Wilcoxon Rank p=0.02 and p=0.03, respectively for   V!! and   V!!"; Figure 3). 
Direct contrasts between healthy controls   V!!"  and MS patients   V!!"#!  and V!!""#  V!!""# demonstrated trends to greater binding in the patients’ VOIs (Wilcoxon 
Rank p=0.09 and p=0.06, respectively; Figure 4.4 and 4.5). 
I noted a particularly low VT for one of the patients within the HAB group, across all 
VOIs, as illustrated in Figure 4.5 (MS patients, case 11). The VT was significantly 
lower than that of all other MS patients in the HAB group, and this appeared 
unexpected. There were no demographic or clinical features that would clearly 
differentiate this patient from others in our population, other than a relatively short 
duration of disease (2 years). To rule out any problems in the VT quantification, I 
carefully inspected the fit of the TACs across VOIs, the plasma SUV and the parent 
fraction data to identify any clue that could have caused an abnormally low VT value 
in this HAB patient. However, no abnormality was identified and the patient was 
included in the analysis despite being an outlier. 
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* p< 0.05 vs healthy volunteers   V!!"       § p<0.05 vs   V!!"#$      † p<0.005 vs   V!!"#$ 
 
Figure 4.4  18F-PBR111 uptake in healthy volunteers and across MS patients 
VOIs 
The line in the middle of the boxes are median values, while the hinges represent the 
25th and the 75th percentile respectively. Whiskers represent the maximum and 
minimum values.  
Between-groups contrasts showed: MS patients’ 18F-PBR111   V!!  and   V!!" > healthy 
volunteers’   V!!" (Wilcoxon Rank p<0.05). Within MS patients contrasts showed:   V!! 
>   V!!"#$   and   V!!"  >   V!!"#$  (Wilcoxon Rank p<0.05), and   V!!""#  >   V!!"#$ 
(Wilcoxon Rank p<0.005). 
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Figure 4.5 Individual 18F-PBR111 uptake across white matter VOIs  
Symbols represent separate subjects. For lesional and perilesional VOIs, each symbol 
represents the mean 18F-PBR111 uptake for each patient across all lesions and 
perilesional volumes, respectively. In the legend, each symbol is numbered according 
to the cases’ numbers listed in Table 4.1. The shapes of the symbols indicate the 
binding affinity classes: triangles for LABs, stars for MABs, and circles for HABs. 
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Gadolinium-enhancing lesions. The volume of the two Gadolinium-enhancing 
lesions was 16 mm3 (lesion 1) and 8 mm3 (lesion 2) respectively. There was a 23% 
increase in 18F-PBR111 VT relative to NLHM volume in lesion 1, while in lesion 2 
there was no change in 18F-PBR111 VT relative to NLHM volume. In perilesional 
volumes, the increase in 18F-PBR111 VT relative to NLHM volume was 10% and 1%, 
for lesion 1 and lesion 2 respectively. The volume of these lesions was very small, 
especially for lesion 2 where the volume corresponded to only one voxel in a 
2x2x2mm space.  
4.3.2 Within Subjects contrasts 
Relative 18F-PBR111 VT values for individual lesions and perilesional volumes, and 
in the NLHM and NLLM voxels, are presented separately for each MS patient (see 
Figure 4.6).  The median CV in  V!! across individual lesions within the patients was 
15.2% (range, 9 - 25%).   
Within MS patients, I found an increased VT in lesional (ΔL, 10.7% (-9.5 – 35.6) 
[median (range)]; Wilcoxon Rank p=0.03), perilesional (ΔPL 5.2% (-3.5 – 14.6); 
Wilcoxon Rank p=0.01) and NLLM volumes (ΔNLLM 1.2% (0 – 2.4); Wilcoxon Rank 
p=0.004) relative to the VT in NLHM volumes.  The increased VT in NLLM volumes 
was very small but consistent across all subjects. The maximum 18F-PBR111 uptake 
increase relative to NLHM volumes was higher in lesions (89%) than in the 
perilesional volumes (54%). 60% of lesions and 67% of perilesional volumes had 
higher 18F-PBR111 VT relative to NLHM.   
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Figure 4.6 Relative 18F-PBR111 uptake across lesions, perilesional volumes 
and non-lesional white matter with low MTR 
Relative 18F-PBR111 uptake (relative to the NLHM white matter) in NLLM white 
matter, in individual T2-FLAIR lesions and in perilesional volumes for the MS 
patients studied. The ordinant represents the relative difference in 18F-PBR111 VT in 
lesions (¯), perilesional volumes , and in NLLM white matter (á) relative to 
normal-appearing white matter (NLHM). On the abscissa, MS patients (see Table 4.1) 
are separately indicated. 
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Partial Volume correction: The relative increase in 18F-PBR111 VT in the two 
lesions (case no. 9, Table 4.1) examined after PVC were higher than pre-PVC (post-
PVC ΔL, 59.8% and 102.5%; pre-PVC ΔL, 34.7% and 40.7%, respectively). The 
relative increase in 18F-PBR111 VT vs NLHM in perilesional volumes was not 
meaningfully altered by PVC (post-PVC ΔPL, 18.9 % and 17.5%; pre-PVC ΔPL: 
17.9% and 20.8%, respectively). 
 
Figure 4.7 (A-C) overlays locally thresholded 18F-PBR111 VT increases on T2-
FLAIR hyperintense volumes in two patients with different clinical characteristics. In 
a patient who had experienced high disease activity (5 relapses in the last 2 years; 
Table 4.1, case 9), T2-FLAIR hyperintense lesion areas correspond to areas of 
increased 18F-PBR111 signal. Conversely, in a patient with a more benign disease 
course and with no history of new neurological symptoms reported over the past 2 
years (Table 4.1, case 4), focal areas of increased radiotracer binding correspond 
poorly with T2-hyperintense regions of white matter (Figure 4.7, D-F). 
Disease severity, as assessed from MSSS scores, correlated with the mean 18F-
PBR111 VT increase in lesions for each patient (expressed relative to that in 
individual NLHM white matter) (Spearman’s ρ=0.62; p=0.05; Figure 4.8). The 
relationship of MSSS scores to 18F-PBR111   V!!"#$ and to the lesion load in the white 
matter was also examined, and I found no significant correlation to any of these two 
variables (Spearman’s ρ=-0.3, p=0.38  and ρ=-0.39, p=0.26, respectively). 
 
  
	  	  
111 
 
Figure 4.7  Overlap between T2 FLAIR lesions and 18F-PBR111 VT  
A, D) T2-FLAIR images    B, E) 18F-PBR111 VT parametric maps, overlaid (in warm 
colors) on T2-FLAIR images, and   C, F) overlap between T2-FLAIR lesions (marked 
in blue) and 18F-PBR111 VT (in warm colors) from two illustrative patients. The 
lower threshold for VT parametric maps corresponds to the value of 18F-PBR111 VT in 
the NLHM volume for each of the two patients. The upper threshold is twice the VT 
in the NLHM. 
The upper row illustrates a patient with recent active disease (Table 4.1, case 9). Here, 
T2-FLAIR hyperintense lesional areas correspond to areas of increased 18F-PBR111 
signal. The lower row illustrates a patient (Table 4.1, case 4) with a relatively benign 
disease course showing focal regions of increased 18F-PBR111 VT that correspond 
poorly to T2-FLAIR hyperintense areas.  
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Figure 4.8 Relationship between lesional increase in 18F-PBR111 uptake and 
disease severity 
Positive relationship between MSSS scores and 18F-PBR111 uptake in lesions  
(expressed relative to that in normal-appearing white matter) (Spearman’s ρ=0.62; 
p=0.05).  
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4.3.3 Test-Retest reproducibility  
The test-retest variability in 18F-PBR111   V!!" across subjects (four healthy 
volunteers, one MS patient) was 23% (12% - 55%) [median (range)].  The test-retest 
variabilities in 18F-PBR111   V!!   and   V!!"  across the 18 T2-hyperintense lesion 
volumes identified in the MS patient who was studied twice on consecutive days were 
25% (12% - 57%) and 27% (17% - 36%), respectively, while the median test-retest 
variabilities for the normalised DVRL and DVRPL were 8% (range 1%-31%) and 4%  
(range 0%-9%), respectively. 
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4.4 Discussion 
TSPO PET can be used to assess the innate immune response in patients with MS in 
vivo, although methodological and technical challenges have limited its wide 
application.  I have illustrated how corrected, quantitative measures with a 2nd 
generation TSPO radioligand, 18F-PBR111, promise new insights concerning clinical-
pathological correlations relevant to disease progression. I found increased 18F-
PBR111 VT in the white matter lesional and perilesional volumes of MS patients 
compared to healthy volunteers. 18F-PBR111 VT was higher in lesions, perilesional 
and non-lesional volumes with decreased MTR in MS patients relative to the normal-
appearing white matter of the same subjects.  Moreover, relative 18F-PBR111 VT 
increase in the MS lesions was positively correlated with disease severity, adding to 
recent in vivo data consistent with a role for the innate immune response in the 
progression of neurodegeneration in MS (Giannetti et al., 2014).  
Post-mortem autoradiographic studies in brains of patients with MS have consistently 
demonstrated that increased uptake of TSPO-targeted radioligands co-localizes with 
markers of activated microglia (Banati et al., 2000; Owen et al., 2010; Venneti et al., 
2008; Vowinckel et al., 1997). An immunohistochemical analysis of post-mortem MS 
brain tissue was largely consistent with these findings, suggesting that most cells 
expressing TSPO in acute MS lesions were macrophages or microglia (Cosenza-
Nashat et al., 2009), although it should be cautioned that antibody-based localization 
of the TSPO peptide and expression of the binding domain for the TSPO radioligands 
need not be the same. In a relapsing-remitting EAE model (Mattner et al., 2013), 
increased 18F-PBR111 uptake co-localizes with activated microglia and macrophages 
and parallels the temporal dynamics of their up regulation during experimentally 
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induced relapses.  
I observed an increased 18F-PBR111 uptake in approximately two-thirds of MRI-
defined lesions and perilesional volumes in MS patients relative to their normal 
appearing white matter (NLHM). Ex vivo pathology studies show that acute, active 
lesions are characterised by a hypercellular inflammatory core, marked by prominent 
lymphocyte infiltration with high density of activated microglia and macrophages 
distributed evenly throughout the lesion (Trapp et al., 1999). Case 9 (Figure 4.7, top 
row) illustrates the strong co-localisation of increased 18F-PBR111 VT with T2-
hyperintense lesions in active disease.  In chronic active lesions, microglia are 
increased relative to distant normal white matter tissue and are more concentrated at 
the lesion edge than within the lesion. The hypercellular margin, characterised by a 
high density of activated microglia surrounding demyelinating plaques, is a consistent 
finding across neuropathological studies (Boyle and McGeer, 1990; Lucchinetti et al., 
2000; Marik et al., 2007).   
By contrast, approximately one third of the MRI-defined lesions and perilesional 
volumes were associated with 18F-PBR111 uptake similar to, or lower than, that of the 
normal appearing NLHM white matter. Case 4 (Figure 4.7, bottom row) is an 
illustrative example of poor correspondence between areas of increased 18F-PBR111 
VT and T2 FLAIR hyperintensities. I speculate that these volumes represent chronic 
inactive lesions that are hypocellular or have enlarged extracellular spaces leading to 
a relatively low density of all cells, including microglia. My findings of regional 
variation thus are consistent with post-mortem pathology observations in MS patients.  
The median within-subject CV in lesional 18F-PBR111 uptake was above 15%. This 
indicates a moderately high variability of the observed 18F-PBR111 signal between 
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the T2-hyperintense lesions even within a single MS patient, and further highlights 
that T2-hyperintense MRI contrast change reflects a wide range of neuropathology in 
MS lesions non-specifically (Bruck and Stadelmann, 2005).  
An elegant study by Moll et al. (2011), using combined post-mortem pathology and 
MR imaging, reported that regions appearing normal on T2-weighted MR, but 
displaying reduced MTR, were associated with microglial activation and axonal 
degeneration. By applying the same image segmentation approach as Moll et al., I 
observed a consistently, albeit very small, increased 18F-PBR111 uptake in regions 
with reduced MTR (NLLM) across my study group. Nevertheless, there must be 
caution in interpreting this observation, as it is not clear what could be the true 
biological significance of a relative increase as small as that observed in the NLLM 
volume (1.2%). 
Focal areas of activated microglia identified neuropathologically in white matter areas 
without apparent loss of myelin (Henderson et al., 2009; Marik et al., 2007) may 
represent areas at risk for the development of acute inflammatory lesions.  They have 
been described previously as “pre-active lesions” (De Groot et al., 2001) or regions of 
chronic microglial activation that may contribute independently to progressive 
neurodegeneration (Smith and Lassmann, 2002). Alternatively, white matter 
microglial activation in the absence of inflammatory demyelination may represent 
secondary reactive changes, perhaps associated with Wallerian degeneration (Singh et 
al., 2013).  Direct tests of these alternative hypotheses now seem possible using serial 
MRI observations to follow the course of these white matter changes identified by 
TSPO PET.  
Although this work has gone further than previous studies in using a second 
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generation TSPO radioligand for MRI image-correlated quantitative analyses, my 
findings are in general agreement with those of some TSPO-targeted PET studies in 
MS. Previous work using 11C-(R)-PK11195 demonstrated increased uptake to 
correspond to white matter Gadolinium-enhancing lesions (Banati et al., 2000; 
Debruyne et al., 2003; Vowinckel et al., 1997).  One early study suggested the 
presence of focal areas of increased uptake in normal appearing white (and grey) 
matter (Banati et al., 2000). This was confirmed by a recent study by Rissanen and 
coworkers in secondary progressive MS, that found increased 11C-(R)-PK11195 
uptake in periventricular areas and in the normal appearing white matter, relative to 
healthy controls (Rissanen et al., 2014). However, patterns of ligand uptake in T2-
weighted hyperintensities, and correlations between 11C-(R)-PK11195 uptake and 
disease duration and disability have been inconsistent in previous studies (Banati et 
al., 2000; Debruyne et al., 2003; Versijpt et al., 2005).  This could reflect differences 
in patient populations, differences in the proportion of specific (displaceable) signal 
between 18F-PBR111 and 11C-(R)-PK11195 or accurate modeling, which is 
particularly challenging for the lower affinity 11C-(R)-PK11195 (Giannetti et al., 
2014; Yaqub et al., 2012). 
This is the first study using a 2nd generation TSPO ligand to successfully detect 
significant differences in radioligand uptake between MS patients and healthy 
controls. The lack of differences seen in previous studies may be explained by failure 
to control for the variance introduced by the rs6971 TSPO SNP (Oh et al., 2011; 
Takano et al., 2013).  
There are a number of limitations of my analysis. I studied only a small number of 
patients. Further characterisation of the heterogeneity of the disease is needed. The 
use of disease-modifying treatments in the majority of MS patients studied may have 
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influenced the 18F-PBR111 signal. A study by Ratchford and colleagues showed a 
3.2% reduction in 11C-(R)-PK11195 in relapsing-remitting MS patients after 1-year 
treatment with glatiramer acetate, for example (Ratchford et al., 2012). This estimate 
of treatment effect is much lower than the differences in binding I found between 
healthy volunteers and patients overall, however (approximately 40% in the whole 
white matter).  However, in future work, it will be important to investigate the effects 
of various MS treatments on TSPO specific binding.  
MS patients and healthy controls were not matched for gender, although to my 
knowledge there have been no reports of a gender effect on TSPO binding in humans. 
Studies in rodents suggested a higher number of microglia and astrocytes in adult 
females (Mouton et al., 2002; Schwarz et al., 2012), so I cannot exclude the 
possibility that a higher prevalence of women in the MS group may have contributed 
to the higher 18F-PBR111 VT in patients. 
Finally, increased TSPO is seen not just in activated microglia, but also in rare, 
activated astrocytes (Cosenza-Nashat et al., 2009) and in lymphocytes (Berkovich et 
al., 1993), as well as in brain vascular endothelia (Turkheimer et al., 2007).  The 
interpretation of increased 18F-PBR111 VT reported here as arising largely from 
activated macrophages or microglia is based on prior neuropathological studies 
demonstrating large numbers of these cells post-mortem in the regions studied and on 
the relatively high binding to them relative to other inflammatory cells (Boyle and 
McGeer, 1990; Lucchinetti et al., 2000; Marik et al., 2007; Trapp et al., 1999). A 
contribution from other inflammatory cell types cannot be excluded, but binding 
(Bmax) to lymphocytes is relatively much lower (Canat et al., 1993).  
I found considerable variability in 18F-PBR111 VT between subjects, independent of 
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their TSPO genotypes.  The positive correlation between age and binding may explain 
some of this (Guo et al., 2013), but other factors also must contribute. The assessment 
of test-retest reproducibility of VT demonstrated moderate measurement variance. 
One contribution to this can arise from identification of the true parent plasma input 
function.  TSPO is abundant in the body and blood. Variation in the proportions of 
any displaceable (specific) and non-displaceable (non-specific) binding signals in 
plasma and tissue can also lead to variability.  Consistent with these hypotheses, I 
found that the test-retest reproducibility of lesional and perilesional signal in MS was 
significantly improved after normalisation by correction for normal-appearing white 
matter signal with normal MTR. Normalisation of focal signal intensity in T2-MRI 
lesions by correction for NLHM values may be a particularly useful approach for 
increased precision of assessments in longitudinal studies.  
The extent of inter-subject variability despite correction for genotype, and the 
relatively large overlap of 18F-PBR111 signal between control and patient populations 
are consistent with data obtained with other 2nd generation TSPO radioligands in MS 
and other neuroinflammatory diseases (Kreisl et al., 2013b; Oh et al., 2011; Takano et 
al., 2013).  This may indicate that clinical applications of TSPO PET imaging 
will   require large sample sizes to detect increases in microglia activation in patient 
populations. In longitudinal applications, the use of normalisation (as suggested 
above) would reduce test-retest variability, increasing precision of the assessments, 
but may potentially lead to underestimation of changes in binding over time.  All 
together these are limitations that may blunt the sensitivity of TSPO PET for detection 
of neuroinflammatory processes in vivo.  
A number of methodological aspects are worth considering. Partial volume effect may 
have confounded accurate measurement of binding and led to the underestimation of 
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increases of TSPO binding in lesional VOIs. This should influence estimates in 
smaller regions to the greatest extent, but I have found no evidence that smaller 
volumes were associated with lower increases, suggesting that this was not a 
dominant effect. Furthermore, PVC applied to two large lesional volumes as an 
exploratory tool, suggested that tissue differences may be underestimated due to 
volume averaging. In fact, the relative increase in 18F-PBR111 uptake in lesions were 
enhanced after PVC. However, as PVC did not affect the relative increases in 
perilesional volumes, it is unlikely that my observation of increased TSPO uptake in 
perilesional white matter was artifactually confounded by partial volume effects. 
As 18F-PBR111 VT reflects both displaceable (presumed specific for TSPO) and non-
displaceable (non-specific or off-target binding) binding, the true differences in 
inflammatory response between VOIs may be underestimated. I estimate that the 
proportion of 18F-PBR111 VT corresponding to specific signal ranges between 30 and 
70% across genotypically defined binding affinity classes (Guo et al., 2013). The 
observed increases in lesion associated signal, (ranging between 15 - 50% relative to 
the normal-appearing tissue) therefore suggests an increase in microglia-related TSPO 
binding of between 20 - 80% across different lesions.  
While a 2TC kinetic model has been found to fit the data well, we have observed that 
VT increases slightly with time for reasons not yet well understood (Guo et al., 2013). 
This could have been due to some small, irreversible contribution, e.g., from slow 
entry of a radiolabelled metabolite into the CNS and its non-specific association. I 
attempted to control for this in my analysis by applying a correction factor to the 
values obtained with shorter scan durations intended to minimize biases due to 
underestimation of the signal.  If the statistical analysis were run without the three 
subjects with shorter scan duration, I would have observed significant higher VT in all 
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MS patients’ ROIs (including NLHM and NLLM) relative to healthy controls   V!!" 
(all p<0.05). The correlation between MSSS severity and 18F-PBR111 VT increase  in 
lesions would have remained significant (r=0.76; p<0.05) while the partial correlation 
between disease duration and   V!!" in HABs would have lost significance (r=0.88; 
p=0.12), however only 5 subjects would have been left for this analysis.  
Finally, it is worth mentioning that two MS patients were on natalizumab treatment at 
the time of the 18F-PBR111 scan (Table 4.1). Natalizumab treatment reduces the 
relapse rate in MS patients more effectively than other available treatments 
(Mellergard et al., 2010; Stuve and Bennett, 2007). I hypothesize that treatment with 
natalizumab in those two patients may have reduced 18F-PBR111 binding to a greater 
extent than was apparent in other patients treated with interferon-β, however further 
research is necessary to differentiate the effects on TSPO specific binding of specific 
disease-modifying treatments for MS.  
In conclusion, this study demonstrates that quantitative TSPO PET with a 2nd  
generation radioligand is sensitive to an element of the inflammatory response in MS 
not apparent on MRI and so otherwise occult in vivo. It highlights opportunities for 
the integration of MRI and molecular imaging for understanding the evolution of the 
dynamic neuropathology of MS.  
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Chapter 5. Assessment of hippocampal 18F-PBR111 binding 
and its relationship to depressive symptoms in patients with 
Multiple Sclerosis 
5.1 Introduction 
MS is associated with a higher prevalence of depression relative to that of the general 
population (Kessler et al., 2003), and the prevalence of depression in MS exceeds that 
associated with having one or more other long-term disabling conditions (Patten et al., 
2003).  
A causal association between the activation of innate immunity and the development 
of depression has been proposed. The action on the brain of pro-inflammatory 
mediators, such as cytokines (for example interneukin-1α and β, interleukin-6, tumor 
necrosis factor-α) leads to a potent modulation of affect, resulting in “sickness 
behaviour” and, in vulnerable individuals, to the development of depressive 
symptoms (Dantzer et al., 2008). It is therefore possible that the increased prevalence 
of depressive symptoms in MS patients is a direct consequence of the chronic 
neuroinflammatory injury characteristic of MS pathology.  
MRI studies have reported associations between depressive symptoms in MS patients 
and various parameters, such as the T1-weighted or T2-weighted lesion load, the 
localization of lesions to areas important for mood disorders, the extent of brain 
atrophy, and abnormalities in diffusion   parameters. However, each of these 
associations accounted for only a small amount of total variance in depressive 
symptoms and specific associations have not been consistent across studies (Feinstein 
et al., 2014).  As structural MRI-based alterations reflect a wide range of 
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neuropathological abnormalities, these studies also provide a limited insight into 
mechanisms underlying contributions of neuroinflammation to the pathophysiology of 
depression in MS. 
Convergent lines of research implicate the hippocampus in the pathogenesis of 
depression (MacQueen and Frodl, 2011). Hippocampal atrophy is a well-characterised 
finding in patients with Major Depressive Disorder (MDD) and has been proposed to 
predispose to MDD (Cole et al., 2011).  Hippocampal volume loss and altered 
morphology have been found to associate with depressive symptoms of MS patients 
(Gold et al., 2010; Gold et al., 2014; Kiy et al., 2011).  
The hippocampus (HC), well recognised as involved in the modulation of affect, is 
highly susceptible to neuroinflammation and has the highest concentration of brain 
receptors for the pro-inflammatory cytokine interleukin-1 (Parnet et al., 2002). Post-
mortem and imaging studies have found evidence of extensive demyelination, 
microglia activation, neuronal loss (Geurts et al., 2007; Papadopoulos et al., 2009) 
and atrophy in the hippocampus of MS patients (Sicotte et al., 2008). Hippocampal 
neuroinflammation in the rodent experimental allergic encephalomyelitis model is 
associated with dysfunctional neurogenesis (Giannakopoulou et al., 2013) and 
hippocampal neurogenesis may be critical to recovery from depression (Dranovsky 
and Hen, 2006).   
Here I describe the use of TSPO-targeted 18F-PBR111 PET as a measure of activated 
microglia to characterise hippocampal neuroinflammation in MS patients and to study 
the relationship between this hippocampal neuroinflammation and depressive 
symptoms.   I have evaluated the distribution of the 18F-PBR111 PET signal in the 
cortical grey matter and the hippocampus and other limbic regions in brains of MS 
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patients and healthy controls. I then tested for differences between MS patients and 
healthy controls in the binding ratio (the DVR) of hippocampus, and two other brain 
regions (thalamus and brainstem), to that of the general cortical regions. All 
comparisons were controlled for age and the rs6971 polymorphism that determines 
binding affinity of 2nd generation TSPO radioligands to TSPO (Guo et al., 2013). 
Finally I assessed the relationship of relative hippocampal 18F-PBR111 binding to the 
symptoms and diagnosis of depression in the MS patients, controlling for age and 
disability.  
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5.2 Methods 
5.2.1 Study design 
After baseline screening for eligibility, the MS patients and healthy controls returned 
to the research centre for an MRI/18F-PBR111 PET scan visit within approximately 
one week (see chapter 2 for details). All study subjects underwent a full medical, 
neurological and psychiatric examination at screening. This included administration 
of a structured diagnostic clinical interview based on criteria in the Diagnostic and 
Statistics Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV TR) 
(American Psychiatric Association., 2000), and the administration of a self-reported 
clinical questionnaire for assessment of depressive symptoms (see clinical 
assessments section for details). All subjects were genotyped for the rs6971 SNP.  
5.2.2 Study sample 
Eleven patients with relapsing remitting MS [age, 45.1 ± 8.9 years (mean ± SD); 10 
females] and 22 healthy controls (age, 49.8 ± 11.1 years; 14 females) were studied. 
The self-report questionnaire for depression was not administered to 7 of the healthy 
controls. Further details on subjects, including recruitment strategies, eligibility 
criteria, ethics approval, and full clinical assessments are provided in Chapter 2. The 
clinical and demographic characteristics of subjects, as well as the concomitant 
disease-modifying treatment used, are listed in Table 4.1. Pharmacological treatments 
prescribed for the MS patients had not been changed for at least 3 months prior to 
scanning. No subject received steroid treatment in the month before the PET scans. 
6/11 MS patients were on antidepressant medications. Of these, four patients were 
treated with Selective Serotonin Reuptake Inhibitors (citalopram, n=2; sertraline n=1; 
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fluoxetine, n=1), one patient with mirtazapine, while another patient was receiving a 
tricyclic antidepressant (amitriptyline). 
Subjects were stratified into three groups on the basis of their TSPO rs6971 SNP 
genotype: HABs, MABs, or LABs (Owen et al., 2012).  
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Case Age Gender TSPO 
gene 
group 
Disease 
duration 
(years) 
EDSS BDI MDE  
 
HV1 45 F MAB   6 None 
HV2 36 F MAB   0 None 
HV3 33 F HAB   9 None 
HV4 52 F LAB   0 None 
HV5 61 F MAB   0 None 
HV6 42 F HAB   0 None 
HV7 52 F HAB   1 None 
HV8 43 M MAB   0 None 
HV9 50 F HAB   4 None 
HV10 28 M HAB   1 None 
HV11 52 F HAB   0 None 
HV12 51 M LAB   0 None 
HV13 65 M LAB   8 None 
HV14 28 M HAB   2 None 
HV15 57 M MAB    None 
HV16 59 F HAB    None 
HV17 59 M HAB    None 
HV18 62 M HAB    None 
HV19 60 F MAB    None 
HV20 60 F MAB    None 
HV21 56 F MAB    None 
HV22 44 F LAB    None 
MS1 48 F HAB 8 6.5 23 Current 
MS2 39 F LAB 20 4 9 Recent 
MS3 40 F HAB 11 4 24 Current 
MS4 55 F HAB 20 2 5 None 
MS5 53 F LAB 20 7 30 Current 
MS6 50 F HAB 2 4 10 Current 
MS7 59 F MAB 16 3 8 Recent 
MS8 41 F HAB 14 1.5 3 None 
MS9 28 M HAB 7 2 14 Recent 
MS10 41 F MAB 4 5.5 7 None 
MS11 42 F HAB 1.5 6 19 Current 
Table 5.1 Clinical and demographic characteristics of study participants  
HC: healthy controls MS: multiple sclerosis patient; HAB: high affinity binder; MAB: 
mixed affinity binder; LAB: low affinity binder; BDI: Beck depressive inventory; 
EDSS: expanded disability status scale; MDE; major depressive episode; TSPO: 
18kDa Translocator Protein.  
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5.2.3 Psychiatric diagnosis and clinical assessments  
Diagnoses of Major Depressive Episode (MDE) were made at screening visit by an 
experienced psychiatrist. For this purpose the Mini Neuropsychiatric Interview 
(MINI) (Sheehan et al., 1998), based on DSM-IV diagnostic criteria, was used. 
Current and recent (within the past six months) MDEs were recorded. The Beck 
Depressive Inventory-II (BDI-II) (Beck et al., 1996) was used for assessment of 
depressive symptoms. The BDI-II is a multiple-choice self-report scale consisting in 
21 items. Patients are asked to rate how they have been feeling for the past two 
weeks.   For each item, scores range between 0 and 3.  Disability was assessed at 
screening by an experienced neurologist using the EDSS. 
5.2.4 Definition of Volumes of Interest 
Three anatomically-defined brain areas were evaluated: the hippocampus, my a priori 
chosen VOI, plus the thalamus and brainstem as control VOIs to test whether any 
observed increase in TSPO was hippocampus-specific or global. The choice of 
thalamus and brainstem as control VOIs was based on their potential for accurate 
segmentation and high TSPO signal.  The brainstem volume included medulla, pons, 
and midbrain. A VOI encompassing the entire cortical grey matter was used as a 
pseudo-reference region (see Figure 5.1 and text below for details). 
The amygdala is also an important region for the pathophysiology of affective 
disorders, as it has a crucial role in the modulation of fear and defensive behaviours 
and aversive responses to threat. However, in my pilot investigation I focused my 
interest on the hippocampus for its known involvement in MS pathology, and for its 
susceptibility to neuroinflammation. Also, the amygdala doesn’t provide a particular 
advantage in terms of potential for accurate segmentation and robust TSPO signal, 
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hence was not chosen as control VOI.	  	  
Although brain regions such as the insula, cingulate cortex, and frontal cortex are also 
very interesting, considering their known role in the pathophysiology of depression, 
they were not included in my analysis. In fact, these neocortical areas are part of the 
cortical gray matter volume that I used as a pseudo-reference region, hence those 
regions were not appropriate VOIs for the calculation of the DVR. For exploratory 
purposes, the differences between MS patients and healthy controls in 18F-PBR111 
VT were investigated and reported in the results section.  
My pre-chosen VOIs (hippocampus, thalamus and brainstem) and the cortical grey 
matter were defined with the ICBM152 template (http://www2.bic.mni.mcgill.ca), 
derived from an average of MRI brain scans from the Montreal Neurological Institute. 
The template was nonlinearly warped to the high-resolution T1-MRI of each 
individual, with Statistical Parametric Mapping 5 (SPM5; Wellcome Trust Centre for 
Neuroimaging). The deformation parameters derived were then applied to a 
corresponding anatomical atlas, the Clinical Imaging Center atlas (Tziortzi et al., 
2011) to bring this into the space of the individual subject. Finally, the MRI image, 
VOIs, and warped anatomical atlas were resampled to match the PET image 
resolution. From the atlas, the three VOIs were automatically defined with SPM5 
(Figure 5.1 A). Due to defluorination of the metabolite (Fookes et al., 2008) 18F-
PBR111 defluorinates in vivo resulting in a relatively high signal in the bones of the 
skull (Carson et al., 2003; Guo et al., 2013) The VOI for the cortical grey matter was 
therefore eroded of 5 mm away from the skull to avoid “spill-in” from uptake of 18F-
fluoride by bone of the skull  (Figure 5.1 B).  
Each VOI then was applied to the dynamic PET data to generate regional TACs.  
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Figure 5.1 Definition of Volumes of interest The top row (A) illustrates the 
definition of the hippocampus using the CIC atlas. The bottom row (B) illustrates the 
definition of the VOI for the cortical grey matter used as a pseudo-reference region 
for the calculation of DVR. The VOI deriving from the anatomical atlas was eroded to 
avoid “spill in” from skull bone uptake of 18F-fluoride produced by metabolism of the 
labeled PBR111. 
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5.2.5 Quantification of  TSPO signal 
18F-PBR111 VT was quantified using a 2TC kinetic model with metabolite-corrected 
arterial input function. Details on18F-PBR111 VT quantification have been provided in 
Chapters 2 and 3. For the study of cortical and limbic distribution of 18F-PBR111 
signal, the Logan graphical method (Logan et al., 1990) was used to estimate the VT 
of each VOI and further applied at the voxel level to produce parametric VT maps.   
I used regional relative 18F-PBR111 binding as an index of the regional density of 
activated microglia.  I calculated the DVR, which was defined the ratio of 18F-
PBR111 VT in a VOI of interest to the 18F-PBR111 VT across the entire cortical grey 
matter.  The use of DVR reduces variability in modeling the brain signal arising from 
imprecision in measurement of blood concentrations by normalising to a reference 
tissue uptake. By dosing so, DVR expresses only a relative signal and global 
differences in the specific binding component cannot be detected. However, my 
analysis was testing for differences in the regional distribution of activated microglia, 
which was assumed to be heterogeneous, rather than for absolute measures of signal 
in any region. The elimination of global differences in the 18F-PBR111 specific signal 
also reduces the between-subject variability associated with the rs6971 polymorphism 
of the TSPO gene (Guo et al., 2013). Use of a region that is recognized to bind TSPO 
radiotracers and in which MS associated increases in binding are observed must be 
taken into account when assessing the magnitude and sign of the DVR for a region of 
interest.   
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5.2.6 Statistical analysis 
Between-groups differences in BDI scores were tested using Mann-Whitney U Test 
for independent samples. The correlations between BDI scores, age, EDSS scores, 
and disease duration were studied using Spearman’s non-parametric correlation. 
To study the distribution of 18F-PBR111 specific signal in cortical and limbic regions 
of healthy controls, I normalised voxel-level VT values for the mean uptake in the 
cortical grey matter (Cort GM), to obtain parametric maps of z scores. Voxel-wise Z 
scores maps were computed as follows: 
 (1) z score(x) = [VT value(x) – mean (Cort GM )] / SD (Cort GM),  
where x represents each voxel of the parametric map. 
Between-groups differences in 18F-PBR111 DVR in the hippocampus, thalamus and 
brainstem were tested using an ANCOVA with 18F-PBR111 DVR in the VOIs as 
dependent variables, controlling for age and rs6971 genotype. Differences in 18F-
PBR111 VT in the ‘reference’ region, the cortical grey matter were also tested. The 
relationship between 18F-PBR111 DVR in the hippocampus and BDI scores was 
tested in MS patients only, using Pearson’s partial correlation, while controlling for 
age, EDSS scores, and disease duration. Statistical analyses were done using SPSS 
20.0. To assess the proportion of variance in BDI scores explained by hippocampal 
18F-PBR111 binding, I first used a linear regression model with BDI scores as 
dependent variable and hippocampal 18F-PBR111 DVR as an explanatory variable. 
Subsequently a second linear regression model was used using BDI scores as 
dependent variable, and hippocampal 18F-PBR111 DVR, age, disease duration and 
EDSS scores as explanatory variables. 
	  	  
133 
5.3 Results 
5.3.1 MDE diagnosis and depressive symptoms in Multiple Sclerosis patients 
5/11 MS patients (45%) met DSM-IV criteria for current diagnosis of MDE, while in 
3 cases (27%) patients met criteria for a past MDE (within last 6 months), but did not 
have active symptoms at the time of examination. None of healthy volunteers had 
current or past MDE.  MS patients had significantly higher BDI scores compared to 
healthy controls (MS, 10 (3-30) [median (range)]; HV, 0 (0-9); Z=4.4; p<0.0001).  
BDI scores were significantly correlated to EDSS scores (Pearson’s r=0.72; p=0.013) 
for MS patients, although there was no correlation between BDI scores and age or 
between BDI scores and duration of disease. 
5.3.2 Distribution of 18F-PBR111 uptake  
Averaged 18F-PBR111 signal (VT) for healthy controls was distributed throughout the 
brain (see Chapter 3). Areas with higher 18F-PBR111 signal, indicative of higher 
TSPO density, included periaqueductal grey, thalami, hippocampi, amygdala, 
cingulate gyrus and insula. 
Figure 5.2 displays normalised z-score parametric maps from 18F-PBR111 VT for 
comparison of the distributions of 18F-PBR111 signal in the cortical and limbic grey 
matter in healthy controls and MS patients. In both groups, the hippocampal signal 
was higher than average cortical grey matter signal. The group map for MS patients 
also highlights increased relative signal in the insula bilaterally. Since the insula is 
included in the pseudo reference region used for the calculation of the DVR, it was 
not possible to assess between groups differences in the insula using the DVR. 
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However, no increase in the insular VT was observed in the MS patients relative to 
controls in my exploratory analysis. 
 
 
Figure 5.2 Distribution of cortical 18F-PBR111 signal in healthy volunteers and 
MS patients  
Parametric maps of normalised 18F-PBR111 VT  (z scores) in the cortical and limbic 
grey matter areas, in healthy volunteers (top row), and MS patients (bottow row), in 
axial, coronal and sagittal views. Values higher than 1 (hot colours) indicate a signal 
higher than average cortical grey matter. Values lower than 1 (cool colours) indicate a 
signal lower than average cortical grey matter. Arrows illustrate the location of the 
hippocampus 
  
	  	  
135 
5.3.3 Between Subjects contrasts of 18F-PBR111 DVR 
18F-PBR111 DVR was higher in the hippocampus of MS patients relative to healthy 
controls [MS patients 1.08 ± 0.04 (mean ± SD); healthy controls 1.03 ± 0.09; t = 2.49; 
p=0.018] (Figure 5.3). The difference remained significant after correction for age 
and rs6971 genotype (F=5.73; p=0.024). By contrast, 18F-PBR111 DVR in the 
thalamus and brainstem did not differ significantly between MS patients and healthy 
controls (Thalamus, MS patients 1.09 ± 0.06, HVs 1.06 ± 0.07; N.s. Brainstem, MS 
patients 1.11 ± 0.14, healthy controls 1.09 ± 0.11; N.s.) (Figure 5.3).  The VT in the 
cortical grey matter was similar between MS patients and healthy controls after 
correction for age and rs6971 genotype (F=0.01; p=0.987). My exploratory analysis 
also revealed that there was no difference in 18F-PBR111 VT in the insula, cingulate 
cortex, and frontal cortex between MS patients and controls (all p>0.9, correcting for 
age and rs6971 genotype). 
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Figure 5.3 Comparison of 18F-PBR111 DVR between groups in the VOIs 
The Distribution Volume Ratio (DVR) of 18F-PBR111 DVR was higher in MS 
patients (red) than healthy controls (black) in the hippocampus but not in the thalamus 
or brainstem. Each dot represents individual subjects’ DVR values. The horizontal 
lines represent group’s mean and standard deviation.  
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5.3.4 Relationship between 18F-PBR111 DVR and MDE diagnosis  
A current MDE diagnosis for MS patients was associated with a higher hippocampal 
18F-PBR111 DVR than in the group of MS patient with no history or with recent but 
resolved MDE (current MDE 1.11 ± 0.018, no history and resolved MDE 1.06 ± 
0.047; t=2.48; p=0.044; Figure 5.4). The hippocampal 18F-PBR111 DVR values of the 
three MS patients with no history of MDE diagnosis (range, 1.028 – 1.057) were 
within the 95% confidence interval for the mean of 18F-PBR111 DVR of healthy 
volunteers (95% CI, 0.98 – 1.066). 
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Figure 5.4 Relationship between MDE Diagnosis and hippocampal 18F-
PBR111 DVR in MS patients 
Recent MDE diagnosis refers to the occurrence of a MDE in the last 6 months that 
has resolved at the time of scanning. 
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5.3.5 Relationship between 18F-PBR111 DVR and depressive symptoms 
I found a positive correlation in MS patients between 18F-PBR111 DVR in the 
hippocampus and BDI scores (Pearson’s r=0.63; p=0.037). The strength of the 
independent relationship was stronger with control for age, disease duration, and 
EDSS scores (Pearson’s partial correlation r=0.863; p=0.006) (Figure 5.5). The 
correlation of BDI scores was specific for 18F-PBR111 DVR in the hippocampus; 
there was no correlation between BDI scores and 18F-PBR111 DVR in the thalamus 
(Pearson’s r=0.17, N.s.) or brainstem (Pearson’s r=0.29, N.s.). 
Linear regression analysis showed that while a model with hippocampal 18F-PBR111 
DVR alone as a regressor explained 33% of the BDI score variance, a model that also 
included hippocampal 18F-PBR111 DVR, age, disease duration and EDSS scores as 
regressors, explained 82% of the BDI score variance.   
  
	  	  
140 
Figure 5.5 Relationship between hippocampal 18F-PBR111 DVR and BDI scores 
 
 
Figure 5.5 Relationship between hippocampal 18F-PBR111 DVR and BDI scores 
Partial regression plot illustrating the correlation between Distribution Volume Ratio 
of 18F-PBR111 in the hippocampus and BDI scores in MS patients (n=11), after 
correcting for age, duration of disease and EDSS scores. Values represent 
standardized residuals of the dependent variable (BDI scores) and 18F-PBR111 DVR 
when both these variables are regressed on the rest of the independent variables (age, 
duration of disease, and EDSS scores). BDI scores are represented on the ordinate, 
while 18F-PBR111 DVR are represented on the abscissa. 
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5.4 Discussion 
I presented the use of the novel TSPO-targeting PET radiotracer 18F-PBR111 to 
assess hippocampal microglial inflammation in patients with relapsing-remitting MS, 
and to investigate whether depressive symptoms are associated with hippocampal 
inflammation.  
PET imaging of the TSPO has long been used as a proxy of microglia activation. 
Specific 18F-PBR111 signal co-localises with markers of activated microglia in 
rodents (Mattner et al., 2013) and, in MS patients in vivo, is increased in brain areas 
that T2-weighted MRI identifies as lesions (Colasanti et al., 2014) (see Chapter 4).  
My finding of a relatively high 18F-PBR111 binding in the hippocampus is consistent 
with previous studies showing that the hippocampus is one of the grey matter regions 
with the highest density of microglia and TSPO binding in healthy subjects (Gulyas et 
al., 2009; Lawson et al., 1990; Mittelbronn et al., 2001).  
I found additionally increased 18F-PBR111 binding in the hippocampus of MS 
patients relative to healthy volunteers. There was no difference in the cortical signal 
normalised radiotracer binding in the thalamus and brainstem, two other large and 
TSPO-dense regions. This observation is consistent with previous data identifying a 
substantial disease burden in the hippocampus. Post-mortem neuropathology 
identifies hippocampal demyelination in brains of 50-80% of MS patients (Geurts et 
al., 2007; Papadopoulos et al., 2009). Activated microglia appear most abundant in 
actively demyelinating lesions or on the edges of more chronically demyelinated 
lesions. Also, post-mortem studies indicated that MS-related hippocampal damage 
increases with increasing disease duration, which would suggest that depressive 
symptoms are more common in secondary progressive MS and worsen with 
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progression. This prediction contrasts with the higher reported prevalence of 
depression amongst patients with relapsing remitting disease relative to secondary 
progressive MS (Feinstein et al., 2014). The presence of higher microglial activation 
in active lesions, characteristics of the relapsing remitting phase, could be a potential 
explanation for these apparently discrepant findings. 
The most important finding of my study was that hippocampal, but not thalamic or 
brainstem, 18F-PBR111 binding was highly correlated to self-reported depressive 
symptoms of patients. Also, hippocampal 18F-PBR111 binding was highest in MS 
patients meeting the criteria for current MDE. Most of the subjects had a lifetime 
diagnosis of depression, and more than half of the MS patients studied were depressed 
at the time of the study, in line with the very high prevalence rates of depression 
reported in hospital-based clinics (Feinstein et al., 2014).  
A link between hippocampal pathology and depressive symptoms in MS patients had 
been suggested previously by structural neuroimaging studies. Gold and coworkers 
reported an association of depressive symptoms with reduced dentate gyrus volume 
and higher cortisol levels (Gold et al., 2010). Kiy and coworkers used temporal horn 
volumetry as an indirect assessment of hippocampal volume in MS patients, and 
found depressive symptoms to be associated with smaller hippocampi (Kiy et al., 
2011). In a follow up paper, Gold et al. described an association between 
hippocampal shape changes in MS patients and the affective component of their 
depressive symptomatology (Gold et al., 2014). My study’s findings provide further 
insight into the relationship between hippocampal pathology and depressive 
symptoms in MS.   They suggest that the action of innate immunity mediators at 
hippocampal level plays a significant role in the pathophysiology of the affective 
dysregulation associated with MS. 
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A role for neuroinflammation in the pathogenesis of depression has been postulated 
more generally.  Epidemiologic studies have shown high comorbidity of depression 
with autoimmune and chronic inflammatory diseases, experimental studies have 
described cytokine-induced sickness behavior, and clinical observations have 
highlighted that immune activation therapies can cause clinically significant 
depression, and that pro-inflammatory cytokine levels are raised in the plasma of 
patients presenting with depression (Miller et al., 2009; Wager-Smith and Markou, 
2011).  Further evidence in direct support of a neuroinflammatory model of 
depression has been provided by studies using in vivo assessment of microglia 
activation with TSPO-targeted PET. An increased binding of first generation TSPO 
tracer 11C-(R)-PK11195 was reported in hippocampus of euthymic bipolar disorder 
patients (Haarman et al., 2014). A recent study reported a global increase of 18F-
FEPPA VT in the brain of patients with depression during a MDE (Setiawan et al., 
2014). However, Hannestad and coworkers did not find differences in 11C-PBR28 
uptake between patients with mild-to-moderate depression and healthy volunteers 
(Hannestad et al., 2013). 
Various mechanisms could underlie the association between hippocampal microglia 
activation and depressive symptoms observed in my study. Microglia-derived 
cytokines enhance enzymatic activity of indoleamine 2,3 dioxygenase (IDO), which 
could cause relative depletion of the serotonin precursor tryptophan and a reduction in 
the availability of serotonin for de novo synthesis, as well as the generation of 
neuroactive tryptophan metabolites that affect glutamatergic signaling at NMDA 
receptor (Dantzer et al., 2008). Pro-inflammatory cytokines also can activate 
hypothalamus-pituitary-adrenal (HPA) axis leading to excessive production of the 
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neuroactive peptide CRH, which in turn might precipitate depressive symptoms 
(Holsboer, 1999).  
This analysis revealed an association between depressive symptoms and 18F-PBR111 
in the hippocampus, but not in the thalamus and brainstem. Some observations 
specifically implicate the hippocampus as a candidate region for the action of 
microglia-produced pro-inflammatory cytokines in mediating depressive symptoms: 
the highest IL-1 receptor density is observed in the hippocampus (Parnet et al., 2002) 
and LPS-induced depressive-like behavior is associated with abnormal cellular 
activity in specific brain structures such as hippocampus, extended amygdala, and 
hypothalamus (Frenois et al., 2007). 
The cross-sectional nature of my study prevents us from making confident inferences 
of causality. Formally, it is difficult to establish whether hippocampal microglia 
activation causes depressive symptoms or vice versa.  I cannot exclude the latter 
possibility; exposure of rodents to chronic stress and social isolation, for example, has 
been shown to cause proliferation, activation, and priming of hippocampal microglia 
(Walker et al., 2013).  It is possible that MS patients, who are in an immunologically 
“primed” state (Ramaglia et al., 2012), may be more likely to manifest such a 
response.  However, the relative anatomical specificity of the microglial response 
associated with BDI is striking.  This important question needs further, longitudinal 
study, e.g., in populations treated with immunomodulators independent of any use of 
anti-depressants to evaluate the independent impact of a reduction of microglial 
activation on affective symptoms. 
Some methodological limitations need to be considered.  The sample of MS patients 
was small.  A larger population is needed to evaluate the generalizability of my 
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observations. Most of MS patients studied were on disease modifying treatment. It is 
likely that this would have an effect, even if indirect, to reduce microglial activation 
and thus may have reduced the magnitude of differences that I observed (Ratchford et 
al., 2012). The interaction between disease modifying therapy, inflammation and 
depression is complex, as some disease modifying therapies, such as interferon-β, are 
themselves associated with depression. All of the patients with prominent depressive 
symptoms also were on antidepressant treatments that could have further confounded 
the relationship between depressive symptomatology and hippocampal inflammation, 
by influencing the expression of depressive symptoms, the activation of microglia or 
both.  In future work, a longitudinal design will be needed to define independent 
contributions of these factors.  Finally, I used the DVR as the outcome parameter to 
decrease variability of measurements and thus make such a modestly powered pilot 
study possible.  Use of a normalised measure may have masked global differences in 
microglial activation, potentially contributing to an artifactually greater focality to 
microglial activation associated with depression.  Alternatively, I cannot exclude that 
the observed between-groups difference could have been driven by a lower 18F-
PBR111 binding in the cortical grey matter (the pseudo-reference region) in MS 
patients, although this direction of effects (decreased microglial activation in 
associated with depression) would be counter to expectations based on other 
observations (Dantzer et al., 2008; Miller et al., 2009; Setiawan et al., 2014).   
Moreover, cortical grey matter 18F-PBR111 VT and the thalamic and brainstem 18F-
PBR111 DVR were similar across groups. 
Despite the several factors that might have confounded detection of an association, 
the results are consistent with my hypothesis that microglial activation in the 
hippocampus is associated with depressive symptoms in patients with MS.  The 
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strong association suggests that it is a major factor and, in conjunction with other 
observations cited above, I believe that it may be causal. In the next chapter I will 
develop additional evidence supporting this hypothesis by investigating neural 
correlates of both hippocampal neuroinflammation and depression in MS patients 
using resting state fMRI functional connectivity.  
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Chapter 6. Relationship of hippocampal 18-F PBR111 
binding and depression to resting-state hippocampal 
functional connectivity in Multiple Sclerosis 
6.1 Introduction 
The previous chapter reports the association between hippocampal neuroinflammation 
assessed with TSPO–targeted PBR111 PET and depressive symptoms in relapsing 
remitting MS patients.  I hypothesise that it is the disruption of hippocampal functions 
caused by direct or indirect actions of activated microglia that leads to depressive 
symptoms.  
Beside its well-characterised role in encoding and retrieval of declarative memories 
and spatial navigation, there is increasing evidence that the hippocampus plays an 
important role in the pathogenesis of depression. Hippocampal atrophy is a 
consistently reported finding in depressed individuals, and has been suggested to 
predispose to the development of depression (Cole et al., 2011). Cognitive 
impairment in depressed individuals notably involved measures of memory functions 
that are heavily dependent on hippocampal function (Zakzanis et al., 1998). 
Connectivity studies have identified the hippocampus as one of the components of a 
network that is dysregulated in depressed individuals, and there are converging lines 
of evidence that the alterations in regulatory functions of the hippocampus, for 
example its modulation of the HPA stress hormone axis or regulation of the function 
of prefrontal, ventral tegmental and striatal areas, contribute to the development of 
depressive symptoms [for review see MacQueen and Frodl (2011)].  
Resting state fMRI allows the study of functional connectivity using the analysis of 
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temporal correlations in spontaneous changes of the BOLD signal in the unstimulated, 
resting brain. Resting-state functional connectivity can be used to assess neural 
functional impairments (Barkhof et al., 2014). 
This study characterised the functional connectivity of the hippocampus in healthy 
controls and MS patients using seed-based approach. I have tested for differences in 
the pattern of hippocampal functional connectivity between MS patients and healthy 
controls. Subsequently, I investigated whether the strength of hippocampal functional 
connectivities varies with the expression of depressive symptoms or with 
hippocampal microglia activation in MS patients as measured with 18F-PBR111 PET.  
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6.2 Methods 
6.2.1 Study sample and design 
Thirteen MS patients and 15 healthy controls underwent resting state fMRI and were 
included in the present analysis. This includes the 11 MS patients whose data was 
included in the previous chapter and 15/22 of the healthy controls described there.  
Demographic characteristics of the study sample are presented in Table 5.1. Details 
on subjects, including recruitment strategies, eligibility criteria, ethics approval, and 
full clinical assessments, as well as concomitant treatment have been previously 
reported.  
6.2.2 fMRI protocol 
Subjects underwent fMRI scanning on the same day as PET scanning, approximately 
1 hour before the beginning of the PET scan.  MR data was acquired on a 3T Siemens 
Verio (Siemens Healthcare, Erlangen Germany) clinical MRI scanner equipped with a 
32-channel phased-array head coil.  Resting state fMRI data was acquired with a 
double-echo gradient echo EPI sequence, acquiring 150 volumes in 5m:06s.  Each 
volume comprised 35 3-mm thick slices in a 225mm FOV, 64x64 matrix size, echo 
times at 13 and 31ms, parallel imaging factor of 2, and a TR of 2 seconds. 
6.2.3 Resting-state functional connectivity analysis 
Each subject’s T1 anatomical images were stripped of their non-brain tissue using the 
brain extraction tool (BET) v2.1 (fractional intensity threshold=0.5, robust brain 
centre estimation). A bilateral hippocampal VOI was defined in standardised 
stereotactic (MNI152) space. The entire hippocampus was defined using a standard 
anatomical atlas (the CIC Atlas, thresholded at 0.5). This template hippocampal 
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region was then registered into each subject’s functional data space using FLIRT 
(FSL’s Linear Registration Tool). Time-series data were then extracted from the 
functional data using the transformed subject-specific hippocampal VOI as a mask 
image.  
The fMRI Expert Analysis Tool (FEAT) v6.00 was used for pre-processing, general 
linear model (GLM) analysis and anatomical registration of the fMRI data. Pre-
processing included temporal high-pass filtering (0.01 Hz), head-motion correction, 
and spatial smoothing with a 5mm FWHM (full-width half-maximum) Gaussian 
kernel. First-level analyses were conducted on each individual subject/scan by 
entering the extracted hippocampal time-course as a regressor, together with head-
motion parameters as regressors of no interest. No haemodynamic modelling was 
added to the hippocampal regressor, as it already represents haemodynamic data. 
Contrasts simply modeled the positive and negative effects of the hippocampal time-
series regressor. The resulting statistical images were registered to the subject’s main 
anatomical image (acquired during the same session) and subsequently non-linearly 
warped to the template T1 anatomical image in standard MNI-space. 
Group-level analyses were also conducted using FEAT, and used a mixed-model 
(FLAME-1) approach to test between-groups differences in order to model both 
within and between-subject variance. Age and gender were included in this model as 
additional regressors of no interest.   
The analysis of correlations of hippocampal functional connectivity to depressive 
symptoms and hippocampal PET signal was exclusively done in MS patients.  18F-
PBR111 DVR and BDI scores were included as regressors of interest in the group-
level model; nuisance regressors were added in the group-level model and these 
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included age, disease duration, and EDSS. In order to maximise sensitivity, fixed-
effects models were used for the analysis of correlations in MS patients. This method 
in general limits the ability of the findings to be generalised to a population, but is 
appropriate for examination of effects in samples of particular patient groups, as used 
here (Friston et al., 1999). 
All statistical images from the group models were thresholded at p <0.05 (or z=2.3; 
cluster-corrected for multiple comparisons). 
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6.3 Results 
6.3.1 Distribution of hippocampal resting-state functional connectivity 
In the healthy volunteers, regions showing significant positive FC with hippocampal 
seed were located in the limbic system (parahippocampal gyrus, amygdala, and 
insula), basal ganglia (putamen and caudate), thalamus, temporal lobe 
(superior/middle/inferior temporal gyri), medial and inferior prefrontal cortex 
(anterior cingulate cortex, subgenual cingulate, inferior frontal gyrus, orbital gyrus), 
parietal lobe (posterior cingulate, precuneus, angular gyrus, postcentral gyrus), 
occipital lobe and the cerebellum (Figure 6.1A). A similar pattern of functional 
connectivity was found in the MS patient group (Fig. 6.1B). 
Whole-brain analyses of functional connectivity to the hippocampus did not reveal 
any significant group differences between MS patients and healthy controls.  
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Figure 6.1 Patterns of significant positive functional connectivity with the 
hippocampal seed in healthy controls and MS patients 
The threshold was set at Z=4, p<0.05 (corrected). The right side of the brain is to the 
left in the figure (images in radiological orientation).  
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6.3.2 Relationships of functional connectivity to 18F-PBR111 DVR and depressive 
symptoms  
The relationship of hippocampal functional connectivity to 18F-PBR111 binding and 
to depressive symptoms was examined only in the MS patient group. 
Whole brain analysis using hippocampal 18F-PBR111 DVR as a regressor of interest, 
and controlling for age, disease duration, and EDSS scores by using them as 
additional regressors, revealed that hippocampal TSPO signal was positively 
correlated with the strength of functional connectivity between hippocampus and 
regions in the prefrontal cortex (anterior cingulate cortex, subgenual cingulate, 
inferior frontal gyrus, orbital gyrus), precentral gyrus and in the parietal  (posterior 
cingulate, precuneus, angular gyrus, postcentral gyrus) and occipital cortices. 
Negative correlations were found in the insula, temporal lobe and basal ganglia 
(ventral striatum, putamen, caudate). Figure 6.2A illustrates the localization of 
clusters showing significant correlations between 18F-PBR111 DVR and strength of 
functional connectivity to the hippocampus.  
A whole brain analysis using BDI as a regressor of interest, and controlling for age, 
disease duration, and EDSS scores, revealed that a pattern of positive correlations 
between strength of functional connectivity to the hippocampus and depressive 
symptoms similar to that of the correlations with 18F-PBR111 binding. BDI scores 
were positively correlated with the strength of functional connectivity between 
hippocampus and loci in the medial prefrontal cortex, cingulate cortex, subgenual,  
orbital, parahippocampal and lingual gyri, the posterior cingulate, precuneus and the 
occipital cortex. Negative correlations were observed in the frontal pole, frontal 
orbital cortex, putamen, insula, middle temporal gyrus, and lingual gyrus. Figure 6.2B 
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illustrates the localization of clusters with significant correlation between BDI scores 
and strength of functional connectivity to the hippocampus.  
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Figure 6.2 Whole brain map of correlations of hippocampal functional 
connectivity to hippocampal 18F-PBR111 binding and depressive symptoms in 
MS patients  
A) Loci with significant correlation between 18F-PBR111 DVR and strength of 
functional connectivity to the hippocampus. B) Loci with significant correlation 
between BDI scores and strength of functional connectivity to the hippocampus. 
Threshold was set at Z=2.3, p=0.05. Loci with positive correlations are displayed in 
red-to-yellow, loci with negative correlations are displayed in blue-to-cyan. 
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Cluster  
Index 
N. Voxels Z-MAX x y z 
Positive correlations 
1 11948 9.81 2 -58 8 
  9.06 2 -82 -10 
  8.42 -2 -76 -8 
  8.18 12 -32 -4 
  7.79 -16 -96 24 
  7.46 -4 -52 12 
2 10958 8.27 -28 34 42 
  7.99 0 64 10 
  7.98 -8 38 -14 
  7.74 -8 40 -10 
  7.72 -22 44 42 
  7.55 -8 34 -14 
3 965 8.91 -22 -20 -18 
  7.42 -20 -24 -12 
  6.02 -32 -34 -18 
  5.46 -18 -36 -2 
Negative correlations 
4 19611 7.02 20 4 -16 
  6.98 18 0 -20 
  6.71 -16 -76 -52 
 
Table 6.1 Anatomical clusters of correlations between hippocampal 18F-
PBR111 DVR and functional connectivity 
The table includes statistical summaries of main anatomical clusters in Figure 6.2 
reporting positive and negative correlations between 18F-PBR111 DVR and functional 
connectivity of the hippocampus. For each cluster I report the total number of voxels 
(N. voxels) that pass significance, and the Z-statistics (Z-Max) and the Montreal 
Neurological Institute coordinates of the main peaks within the cluster. 
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Cluster  
Index 
N. Voxels Z-MAX x y z 
Positive correlations   
1 5685 7.17 0 -58 8 
  7.06 -4 -54 8 
  6.94 -6 -86 -20 
  6.83 12 -32 -8 
  6.8 0 -84 -10 
  6.72 14 -52 2 
2 2583 6.69 -10 36 -16 
  6.58 2 64 12 
  6.22 -16 68 10 
  5.95 0 58 4 
  5.81 -2 30 16 
  5.52 26 42 44 
3 2274 7.43 -28 34 42 
  7.2 -18 48 42 
  7.01 -20 44 40 
  6.56 -20 38 42 
  6.13 -22 46 32 
  5.62 -26 28 46 
4 988 5.35 -30 -26 52 
  5.13 -46 -18 38 
5 797 8.53 -22 -20 -18 
  5.83 -20 -26 -10 
  5.4 -40 -36 -24 
  5.36 -34 -36 -16 
  5.33 -40 -38 -32 
  5.2 -38 -38 -28 
6 515 5.16 26 -26 52 
  5.13 52 -12 44 
Negative correlations 
7 24631 8.17 20 4 -16 
  8.06 -32 -80 -46 
  7.9 -16 -80 -52 
  7.19 38 -78 -46 
8 471 6.34 -12 62 -16 
  5.87 -4 62 -12 
  5.66 6 34 -24 
  5.5 -6 62 -16 
  5.42 -6 54 -22 
 
Table 6.2 Anatomical clusters of correlations between BDI scores and 
functional connectivity 
The table includes statistical summaries of main anatomical clusters in Figure 6.2 
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reporting positive and negative correlations between BDI scores and functional 
connectivity of the hippocampus. For each cluster I report the total number of voxels 
(N. voxels), the Z-statistics (Z-Max) and the Montreal Neurological Institute 
coordinates of the main peaks within the cluster. 
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6.3.3 Inter-relationships between 18F-PBR111 DVR, functional connectivity, and 
depressive symptoms  
There was considerable overlap between loci with correlation of hippocampal 
functional connectivity to 18F-PBR111 DVR and those with correlation of 
hippocampal functional connectivity to depressive symptoms. Figure 6.3 illustrates a 
whole brain “conjunction” map displaying loci where hippocampal functional 
connectivity was correlated to both 18F-PBR111 binding  and BDI scores. Loci with 
positive correlations were localised in the frontal lobe (subgenual cortex, anterior 
cingulate, superior and middle frontal gyri), parietal lobe (precuneus, posterior 
cingulate), and occipital lobe. Loci with negative correlations included insula, frontal 
lobe areas, and putamen 
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Figure 6.3 Conjunction map of correlations of hippocampal functional 
connectivity to both hippocampal 18F-PBR111 binding and depressive symptoms 
in MS patients  
Loci displaying significant correlations between strength of hippocampal functional 
connectivity and both 18F-PBR111 DVR and BDI scores. Loci with positive 
correlations are coloured in copper, while negative correlations are displayed in green. 
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I further explored the relationships between the measures in prefrontal cortical 
volumes. From the “conjunction” map of significant positive correlations of 
hippocampal functional connectivity to both 18F-PBR111 DVR and BDI scores, a 
volume in the prefrontal cortex (Broadman areas 11, 12, 25, corresponding to orbital 
gyrus and subgenual cingulate) was defined (Figure 6.4). The average values of 
functional connectivity to the hippocampus within this volume were computed across 
subjects and plotted against both 18F-PBR111 DVR and BDI scores to illustrate the 
relationship between the three variables, functional connectivity to the hippocampus, 
18F-PBR111 DVR and BDI scores in this locus (Figure 6.4). Controlling for age, 
disease duration, and EDSS scores, there was a moderately strong correlation between 
the strength of functional connectivity to the hippocampus and BDI scores (Partial 
correlation r=0.62) and between the strength of functional connectivity to the 
hippocampus and 18F-PBR111 DVR (Partial correlation r=0.63).  
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Figure 6.4 Relationship between hippocampal functional connectivity, 
hippocampal 18F-PBR111 DVR and BDI scores  
An area of the prefrontal cortex chosen for illustration purposes. The scatterplots 
illustrate the high correlation of these three variables to each other hippocampal 
functional connectivity, hippocampal 18F-PBR111 DVR and BDI scores. Values 
represent standardized residuals of the dependent variables (BDI scores and 18F-
PBR111 DVR, respectively) and standardized residuals of functional connectivity of 
the hippocampus, when all these variables are regressed on the rest of the independent 
variables (age, duration of disease, and EDSS scores).  
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6.4 Discussion 
I evaluated resting-state functional connectivity of the hippocampus in MS patients 
and healthy volunteers, in order to test for a mechanistic basis for the underlying the 
reported association (Chapter 5) between hippocampal neuroinflammation and 
depressive symptoms in MS patients. I described the relationship between the 
strengths of functional connectivity of the hippocampus with the whole brain and 
measures of hippocampal neuroinflammation and depressive symptoms in MS 
patients. 
The patterns of observed functional connectivity of the hippocampal are consistent 
with previous reports. The hippocampus is anatomically connected to the 
parahippocampal gyrus, amygdala, prefrontal cortex, thalamus, and basal ganglia 
(Phillips et al., 2003; Rosene and Van Hoesen, 1977). My findings are in line with 
those of other studies of functional connectivity of the hippocampus, that reported 
functional connectivity of the hippocampus to thalamus, prefrontal cortex, medial 
parietal lobe, posterior cingulate, observed at rest and during execution of memory 
tasks (Cao et al., 2012; Ranganath et al., 2005; Stein et al., 2000; Zarei et al., 2012). 
I did not observe significant differences in functional connectivity of the hippocampus 
between the healthy subjects and the MS patients.  Differences in functional 
connectivity in MS patients relative to healthy subjects have been previously reported 
(Barkhof et al., 2014). It is likely that my study was underpowered to detect any true 
difference, particularly given the heterogeneity amongst the MS patients that was 
highlighted by my parametric analysis.  Previous literature also is consistent with 
population heterogeneity.  Contrasting results have been obtained.  For example, 
while Roosendaal et al. reported reduced resting state hippocampal functional 
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connectivity to anterior cingulate, thalamus, and prefrontal cortex (Roosendaal et al., 
2010), Loitfelder and coworkers found no differences in resting-state functional 
connectivity of hippocampus to anterior cingulate cortex between MS patients and 
healthy controls (Loitfelder et al., 2012).   Finally, therapeutic interventions that have 
been reported to affect the strength of hippocampal functional connectivity also may 
have confounded my results (Leavitt et al., 2014; Prakash et al., 2011). 
The most important observation of this study is the correlation of TSPO signal, 
indicative of microglia activation, to functional connectivity between the 
hippocampus and several brain areas.  A very similar pattern of positive and negative 
correlations was found between BDI scores and hippocampal functional connectivity. 
Although hippocampal 18F-PBR111 DVR and BDI scores are themselves highly 
correlated, the overlap of the precise spatial patterns for correlations of the two 
variables with functional connectivity is striking.  A possible interpretation of these 
results is that modulation of hippocampal connectivities by microglial inflammation is 
a contributing cause of depressive symptoms in patients with MS.  
The functional connections between hippocampus and the above-mentioned regions 
are supported by theoretical models of depression. Neuroimaging, neuropathological, 
and lesion analysis data suggest implicate the hippocampus in an extended anatomical 
network formed by the neural projections of the subgenual and other areas of the 
orbitomedial prefrontal cortex, together with other regions such as amygdala, 
posterior cingulate cortex, ventral striatum and thalamus.  Impaired functions of key 
nodes within this network could dysregulate emotional expression and give rise to the 
clinical signs and symptoms of depression (Drevets et al., 2008; Mayberg, 1997).  
Although my study was unable to directly test whether microglia activation in the 
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hippocampus affects its function, preclinical evidence supports this hypothesis. In 
EAE, hippocampal neuroinflammation alters adult neurogenesis (Giannakopoulou et 
al., 2013) and causes alterations of GABAergic transmission (Nistico et al., 2013). 
This effect is likely to be mediated by activated microglia as incubation of 
hippocampal slices from healthy mice with activated microglia causes similar 
alterations of GABAergic transmission (Nistico et al., 2013). 
My study has been an exploratory pilot.  The sample size was small.  In consequence, 
a fixed effect model was used for my correlation analysis, but this means that 
generalization of my findings to the wider MS population must be made cautiously. 
The small size of the population precluded exploration of the impacts of potential 
confounding factors such as gender, use of concomitant medications, global and 
regional brain atrophy, localization of lesions and alteration in structural connectivity 
in patients. I also have focused my interest only on hippocampal functional 
connectivity because of the prominence of the microglial activation signal in this 
region (see Chapter 5), but it cannot be excluded that hippocampal neuroinflammation 
is associated with alterations in functional connectivity in regions other than the 
hippocampus. 
To my knowledge, this is the first study using a combination of PET imaging of 
microglia and fMRI to investigate clinical-pathology correlations in vivo in MS 
patients.  While conclusions are preliminary, they further support the hypothesis of a 
pathogenic role for hippocampal microglial activation in the genesis of depression in 
MS.   
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Chapter 7. Summary, conclusive remarks and future 
directions 
The studies reported in the present thesis aimed to evaluate the potential of a 2nd 
generation TSPO PET radiotracer as a tool to assess neuroinflammation in the brain 
of patients with MS for the study of clinical-pathological correlations in vivo.  
 
As illustrated in Chapter 3, it was demonstrated that 18F-PBR111 yields a measurable 
signal, which is influenced by rs6971 polymorphism of the TSPO gene, known to 
determine the affinity of 2nd generation radioligands to TSPO, and age. These findings 
confirmed the usefulness of 18F-PBR111 for PET imaging of TSPO in human 
subjects. The observations reported in Chapter 3 also served as guidance for the 
analyses presented in subsequent chapters. Specifically, the data highlighted the 
importance of genotypic stratification of subjects in order to improve both accuracy 
and precision of measurements. Other observations, with high relevance from a 
methodological perspective, included the unexpectedly high variability of 18F- 
PBR111 signal across healthy subjects, despite correction for rs6971 SNP and age 
and, and the finding of significant signal in the skull, probably from 18F released with 
metabolism of the radiotracer, that limits the accuracy of measurements in the cortical 
grey matter. 
My second analysis, reported in Chapter 4, examined 18F-PBR111 uptake in the white 
matter of MS patients. The focus on white matter was based upon the notion that 
activation of microglia is a prominent feature in the MS white matter. My objective 
was to test whether the in vivo signal obtained with 18F-PBR111 PET in MS 
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corresponded to previous neuropathological observations. I segmented the white 
matter into lesional, peri-lesional, “slightly abnormal” and non-lesional brain tissue, 
based on MRI-based measures, and demonstrated that 18F-PBR111 signal in MRI-
defined lesional areas was the highest throughout the MS patients’ brain, and was 
higher relative to that of healthy controls’ white matter. These findings, including the 
observation of high variability between lesions even within the same patient, are 
consistent with neuropathological observations of lesion heterogeneity and suggest 
that the measurement of the relative TSPO signal increase in MRI-defined lesional 
areas could be used to estimate the extent of focal inflammatory activity individually 
across various white matter lesions.  Additionally, an important finding of my 
analyses was the observation of an association between the rate of development of 
disability and the average increase in 18F-PBR111 signal across lesions, relative to the 
normal-appearing white matter, supporting a role for the innate immune response in 
the progression of neurodegeneration in MS.   
In the third and last set of analyses, including the use of resting-state fMRI, I 
examined the association of hippocampal microglial activation with depressive 
symptoms in MS patients and to the strength of functional connectivity of the 
hippocampus to the rest of the brain. The hippocampus is a region vulnerable to 
inflammation, is one of the specific sites of MS pathology, and is involved in the 
pathophysiology of depression. MS patients displayed an increased hippocampal 18F-
PBR111 signal, relative to healthy controls, which was associated with their 
depressive symptoms. Using a multimodal neuroimaging approach, I demonstrated 
that the strength of functional connectivity of the hippocampus to specific areas in the 
frontal and parietal lobes, was correlated to both depressive symptoms and 
hippocampal microglia activation measured with TSPO PET. These findings are 
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consistent with accumulating evidence suggesting a causal role for neuroinflammation 
in the pathogenesis of depression in MS.   
 
This work demonstrated that the integration of TSPO-targeted PET with structural 
and functional MRI provides more specific information on the underlying dynamic 
neuropathology in the MS brain, relative to the use of MRI alone. I feel that my 
research addressed some important research questions and that my findings provided 
a novel insight into the methodology, the underlying mechanisms, and the utility of in 
vivo imaging of neuroinflammation in MS using a 2nd generation TSPO radioligand.  
However, various important research questions remain unanswered and warrant 
further investigation. 
We don’t know whether the signal obtained with TSPO PET imaging reflects a 
particular stage of activation of the microglia. Post-mortem studies using combined 
immunohistochemistry with markers of microglia activation and TSPO 
autoradiography are necessary to clarify this. In Chapter 4, I reported a higher 18F-
PBR111 signal associated with MS lesions relative to other areas of the brain. Various 
cellular types may have contributed to the increased signal observed in lesions, 
including activated microglia, but also activated macrophages in and around the 
lesion, as well as in the perivascular spaces. It is difficult to ascertain what is the 
contribution of the signal coming from microglia activation alone, which limit our 
ability to interpret our findings with precision. 
The results reported in Chapter 4 demonstrated that white matter 18F-PBR111 signal 
in patients with MS was associated with clinical indicators of illness, such as duration 
of disease and rate of progression of disability. In our subsequent analyses, presented 
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in Chapter 5, we found an association between 18F-PBR111 DVR in the hippocampal 
grey matter to the severity of depressive symptoms. It must therefore be considered 
the possibility that the levels of depression in MS patients may affect the relationship 
between TSPO signal white matter and clinical variables (disease duration and MSSS) 
reported in Chapter 4. We have not tested directly this possibility in our dataset, as 
our small sample size would contraindicate the inclusion of too many control 
variables in the correlation analyses. However, the same association between 
depression and 18F-PBR111 signal, was not found for thalamic or brainstem gray 
matter DVR, or for cortical VT, suggesting that it was specific for the hippocampus. It 
is therefore unlikely that the association between clinical indicators of disease and 
TSPO signal in the white matter, is influenced by the levels of depression of MS 
patients. It is also unlikely that the presence of depressive symptoms in MS patients 
have biased the study of differences in TSPO signal between MS patients and healthy 
controls, contributing to the increased 18F-PBR111 signal observed in MS patients. 
Increased microglia activation in the brain of MS patients is a robust and well-
characterised neuropathological finding, while there is very little evidence in post-
mortem studies suggesting a significantly increased density of activated microglia due 
to depression. Similarly, it is unlikely that the presence of antidepressant treatment 
biased the results, since I am not aware of any evidence specifically supporting a 
significant effect of antidepressants in moderating levels of microglia activation.  
A high between-subjects variability of 18F-PBR111 signal was found in healthy 
subjects, even after correction for genotype and age. The factors that determine this 
variability are unknown. It is most likely that biological factors play a dominant role, 
however the physiological mechanisms regulating the expression of TSPO are not 
well understood (Bae et al., 2014; Morohaku et al., 2014).  
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It is possible that the in-vivo TSPO signal in the human brain also reflects a “priming” 
response of microglia to various stimuli able to promote an inflammatory response, 
including systemic inflammation and stress. Systemic inflammation could be 
experimentally modeled using acute administration of E. Coli lipopolysaccharide 
(LPS) and a study in non-human primates suggest that an LPS challenge caused 
robust increase of TSPO PET signal as measured with 11C-PBR28 (Hannestad et al., 
2012). Stress is also a stimulus able to activate brain innate immune responses. 
Rodents studies have shown that acute and repeated stress cause activation and 
proliferation of microglia, shift microglial immunophenotype towards a pro-
inflammatory profile and potentiate sickness behavioural responses to inflammatory 
challenges and other acute inflammatory insults (Nair and Bonneau, 2006; Sugama et 
al., 2007; Sugama et al., 2009; Sugama et al., 2011; Tynan et al., 2010). The 
hippocampus has been the area most frequently implicated in the inflammatory effects 
of stress.  These effects are likely to be mediated by the stress hormones 
glucocorticoids, as direct glucocorticoid administration induces microglia 
proliferation, and inhibition of glucocorticoid signaling abolished the microglia 
response to acute stress (Frank et al., 2012; Nair and Bonneau, 2006). Furthermore, 
early autoradiography studies in rodents demonstrated that TSPO binding in the 
hippocampus is increased in response to acute stressful stimuli, such as acute swim 
stress (Avital et al., 2001), or administration of the anxiogenic beta-carboline (Drugan 
et al., 1995). I am currently setting up a PET study to assess the effect of acute and 
sub-acute glucocorticoid administration on TSPO signal in healthy subjects. 
There have been various challenges during the course of my PhD project. The use of a 
very novel tracer, which had never been characterized in humans before, added 
complexity to my work. Basing an entire PhD thesis on the use of such a novel 
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radiotracer, without available human data, may have represented a high risk plan, that 
could have potentially jeopardized the success of my research project, should I had 
found that the characteristics of the tracer were unpromising for imaging purposes.  If 
this would have been the case, my back-up plan was to switch to 11C-PBR28, another 
2nd generation TSPO tracer.  11C-PBR28 had been developed in Imanova and was 
ready for clinical use simultaneously as 18F-PBR111. 11C-PBR28 had been previously 
characterized by various PET imaging research groups and its excellent imaging 
characteristics were well-known. As explained in the paragraph 1.5.1, one of the 
initial reasons for preferring 18F-PBR111 over other tracers including 11C-PBR28 was 
the relatively small difference in TSPO affinity of 18F-PBR111 across TSPO binding 
groups. During the preparatory phase of my study, my colleague Dr Owen and 
coworkers at Imanova discovered the possibility of predicting TSPO binding status 
with 100% accuracy, by genotyping subjects for the rs6971 polymorphism of the 
TSPO gene. This discovery simplifies the setup and interpretation of studies using 
11C-PBR28 where the differences between binding groups is more marked, since it 
allows identification of the TSPO binding status at screening with a simple genetic 
test, therefore a study in MS patients using 11C-PBR28 would have then been 
perfectly feasible. 
Although the nature of my pilot studies was exploratory and provided preliminary 
rather than conclusive findings, the knowledge acquired with these studies indicated 
the suitability of 18F-PBR111 for TSPO imaging research. Various other TSPO 
tracers, both using 18F and 11C radioisotopes, have been recently developed and 
appear to be also promising tracers. 11C-PK11195 is still very broadly used in many 
PET centres, and has the advantage of producing a signal that is not affected by TSPO 
binding groups, which simplifies the recruitment of study subjects and the logistic of 
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the experiments.  An important question relates to the ideal tracer to be used in future 
TSPO imaging studies. The studies presented in this thesis are unable to specifically 
answer that question as no direct comparisons between tracers have been tested. 
However, in my opinion various conclusions could be drawn indirectly from my 
studies, for guiding the choice of TSPO radiotracers in the future. First, I noted a very 
high between-subjects variability in the TSPO signal with 18F-PBR111, which is 
similar to that reported with all other known TSPO tracers, including 11C-PK11195 
and 11C-PBR28, when similar quantification methods are compared. This means that a 
large number of subjects is always required for cross-sectional investigations, and 
considering the costs and challenges of PET scanning, the possibility of combining 
data acquired in different PET centers, by using the same tracers and the same 
methodology, would be of utmost importance.  If each of the many research groups 
specialized in PET imaging keeps using a different TSPO tracer, it is unlikely that 
meaningful clinical information will be acquired any time soon with TSPO PET 
imaging. Ideally, the perfect candidate tracer for broad use across PET centers will 
need to be not only an excellent tracer in terms of affinity to TSPO and suitability for 
accurate quantification, but also will need to 1) have a reliable and relatively simple 
radiosynthesis procedure; 2) use 18F as radioisotope to facilitate use in centers where a 
cyclotron is not available; 3) not require pre-characterisation of TSPO binding group 
of subjects by genotyping as well as allow the possibility of obtaining measurable 
signals in LAB subjects. Unfortunately no tracer available at the moment has 
simultaneously all these characteristics. 18F-PBR111 displays most, but not all of 
these features. I believe it is preferable than 11C-PK11195 due to higher affinity to 
TSPO, and hence a better signal-to-noise ratio, which is reflected by the excellent 
quality and precision of parametric images obtained with 18F-PBR111 (for example 
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Figure 4.7). Also, I think that 18F-PBR111 is preferable relative to all 11C tracers for 
its 18F-label. It also has a reliable and robust radiosynthesis that hardly fails. It allows 
imaging of subjects with LAB binding status due to the limited difference between 
TSPO binding status groups. However, it has various limitations: the defluorination of 
the tracer to the skull prevents a precise measurement of signal from the superficial 
layers of the cortex, and the differences between binding groups still affect the in-vivo 
signal as demonstrated by our findings in Chapters 3 and 4. Finally, for various 
practical reasons, including the complexity of legal arrangements over its license for 
use in human subjects, its synthesis has not been implemented in many PET centers 
and is unlikely that any time soon it will be used as broadly as 11C-PK11195 or 11C-
PBR28. In summary, I would prefer 18F-PBR111 to other TSPO tracers for multi-
center studies focusing on subcortical brain regions where inclusion of all subjects 
including LABs is important. On the other hand, I would select an alternative high 
affinity tracer, for example 11C-PBR28, for studies looking at the cortical signal, 
where it would be possible to pre-select participants, for example for studies in 
healthy volunteers or for longitudinal within-subject observations. Overall, I think 
further research is still needed to identify an ideal TSPO radiotracer. 
 
Other methodological challenges discovered in this thesis were the issues of time-
stability of VT (Chapter 3), suggesting that the duration of the scan may affect the 
estimation of the signal, and the moderate-poor within-subject variability of the signal 
observed in test-retest observations (Chapter 4). These characteristics are not specific 
to 18F-PBR111, as they have been observed with most TSPO radiotracers tested so far 
when similar quantification methods were used (Coughlin et al., 2014; Endres et al., 
2009; Fujimura et al., 2009; Fujita et al., 2008; Jucaite et al., 2012). My experimental 
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observations suggest possible ways to deal with these problems. With regard to the 
time-stability analysis, since the time-dependent increase in VT is global, as described 
in Chapter 3, it is possible to reduce the scan duration to 60 minutes allowing for a 
consistent underestimation of the signal. It is important that for group comparisons, 
consistent reductions in scan duration are used across groups, assuming that the 
degree of underestimation is homogenous across different clinical populations. 
With regard to the variability in test-retest measurements, we noticed that the use of a 
normalized measure, the DVR, was associated with a significantly improved test-
retest reproducibility of the signal (Chapter 4), which makes this ligand perfectly 
suitable for longitudinal observations. Obviously the use of DVR also assumes that 
the predicted change in signal must be localized and not global, which may not 
always be the case.  
To assess the source of the within-subject variability of TSPO signal, it would be 
crucial to assess the test-retest reproducibility of the specific binding of TSPO 
radioligands (BPND). An accurate quantification of TSPO specific signal in vivo is 
now possible by means of a “blocking” study, in which a TSPO PET radioligand is 
used in combination with the administration of a TSPO “cold” ligand that competes 
for the same binding site, allowing the determination of the “non-displaceable volume 
of distribution” (VND), and hence estimation of the specific TSPO signal (BPND). 
Separate assessment of the within-subject reproducibility of the TSPO specific signal 
could be estimated by a test-retest TSPO blocking reproducibility study.  
Another important methodological remark is related to the implications that the blood 
brain barrier breakdown in acute MS lesions may have for accurate modeling of the 
tracer. In fact, kinetic modelling of PET tracers makes the assumption of passive 
diffusion of the tracer across an intact blood-brain barrier, which is not true for acute 
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MS lesions. A study using 11C-PK11195  in traumatic brain injury (Folkersma et al., 
2009), where blood brain barrier breakdown is also observed, concluded that the use 
of quantification methods using a reference region led to a systemic bias in 
measurement, relative to  a model using plasma input function, and that this was most 
likely due to variability in kinetic parameters related to the delivery of the tracers 
from blood to the tissue. The use of a kinetic model with a plasma input function, as 
that used in my studies, is therefore recommended to ensure precision of 
measurements in studies in MS patients, where blood brain barrier breakdown is 
likely to occur. 
 
My conclusive remarks are related to the potential usefulness of TSPO PET as a 
biomarker for drug efficacy or for patient stratification.  
Longitudinal studies, in particular those testing the sensitivity of TSPO signal to the 
anti-inflammatory effects of immune-modulating treatments, are necessary to fully 
characterize the use of TSPO PET as an imaging marker of neuroinflammation in MS. 
TSPO PET could be a potentially useful biomarker of drug efficacy for early drug 
development and could shed light on the mechanisms underlying the effects of 
immune-modulation on clinical manifestations of MS, including depressive 
symptoms. However, without clear evidence from treatment studies in support to 
these hypothesis, it is impossible to estimate now the exact impact that TSPO PET 
imaging may have for development of new treatments in MS and for studying the 
response to treatment. I feel that this is a highly promising, albeit still very 
unexplored, application of TSPO imaging, and that the field should prioritize this 
particular research question. 18F-PBR111 is a very good candidate for these types of 
studies, however other 2nd generation tracers may be also suitable. The main aspects 
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to consider for the optimization of the longitudinal studies are the need of a consensus 
between PET centres for identification of a “common” TSPO radioligand for 
multicentre use, and the need of careful characterization of test-retest variability of 
specific TSPO signal. Both these aspects have been discussed earlier in this chapter. 
With regard to the potential usefulness for 18F-PBR111, and more generally, TSPO 
imaging, for patient stratification, it must be acknowledged that TSPO PET has been 
used for more than 15 years, since the development of   11C-PK11195, and it has not 
been able to provide a significant advancement in terms of clinical stratification of 
patients yet. In my opinion, it is unlikely that with 18F-PBR111 the situation will 
dramatically improve. The variability between subjects remains high and is only 
partially explained by clinical variables. The effect size of differences between 
subjects is relatively small, and we also need to consider the extreme cost of PET 
imaging and the practical challenges of the radiosynthesis procedure, the need of 
arterial lines and of genetic stratification.  The most compelling research question and 
unmet need with regard to patient stratification, is the ability of a biomarker to predict 
the progression of neurodegeneration of MS. With 18F-PBR111, we did report an 
association between the rate of development of disability and the average increase in 
18F-PBR111 signal across white matter lesions, relative to the normal-appearing white 
matter, suggesting the utility of 18F-PBR111 in monitoring disease progression. 
However, even more important would be the confirmation that TSPO imaging could 
be used to follow progressive neurodegeneration in secondary progressive patients, 
based on the known role of cortical microglial activation in driving disease 
progression. This had been suggested previously by Politis and coworkers, however 
for replication of this observation, it would be important to use a tracer without spill-
over of signal from the skull due to defluorination, as this is known to bias the 
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precision of measurements of the cortical grey matter signal. Based on these 
considerations, I feel that an imminent application in the clinical routine of TSPO 
PET imaging, using 18F-PBR111 or any of the other existing TSPO tracers, is 
unlikely. However, as described in details earlier, there are a number of questions that 
warrant further investigation. Therefore I feel it is still premature to draw a conclusive 
evaluation on the exact role of TSPO imaging for clinical application in MS.   
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